A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Tumors or cancer of the LUNG.
Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A cell line derived from cultured tumor cells.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
The proto-oncogene c-erbB-1 codes for the epidermal growth factor receptor. Its name originates from the viral homolog v-erbB which was isolated from an avian erythroblastosis virus (AEV) where it was contained as a fragment of the chicken c-ErbB-1 gene lacking the amino-terminal ligand-binding domain. Overexpression of erbB-1 genes occurs in a wide range of tumors, commonly squamous carcinomas of various sites and less commonly adenocarcinomas. The human c-erbB-1 gene is located in the chromosomal region 7p14 and 7p12.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
A malignant epithelial tumor with a glandular organization.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The excision of lung tissue including partial or total lung lobectomy.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
A plant genus of the family MYRSINACEAE. Members contain ardisiacrispins (oleanane triterpenoid saponins), ardicrenin, and cyclamiretin.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
An area of water mostly surrounded by land, usually smaller than a gulf, and affording access to the sea.
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.
Disorders affecting the organs of the thorax.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.

Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. (1/7523)

The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.  (+info)

Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. (2/7523)

OBJECTIVE: To determine the sensitivity, specificity, and accuracy of positron emission tomography with 2-fluorine-18-fluorodeoxyglucose (PET-FDG) in the preoperative staging (N and M staging) of patients with lung cancer. The authors wanted to compare the efficacy of PET scanning with currently used computed tomography (CT) scanning. MATERIALS AND METHODS: Results of whole-body PET-FDG imaging and CT scans were compared with histologic findings for the presence or absence of lymph node disease or metastatic sites. Sampling of mediastinal lymph nodes was performed using mediastinoscopy or thoracotomy. RESULTS: PET-FDG imaging was significantly more sensitive, specific, and accurate for detecting N disease than CT. PET changed N staging in 35% and M staging in 11% of patients. CT scans helped in accurate anatomic localization of 6/57 PET lymph node abnormalities. CONCLUSION: PET-FDG is a reliable method for preoperative staging of patients with lung cancer and would help to optimize management of these patients. Accurate lymph node staging of lung cancer may be ideally performed by simultaneous review of PET and CT scans.  (+info)

Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. (3/7523)

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. (4/7523)

Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 years shows that in women specifically, lung cancer incidence is on the rise. It is estimated that 10-20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an effort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using six 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined. The regions of LOH identified included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453. These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.  (+info)

Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. (5/7523)

BACKGROUND: Conventional cytologic analysis of sputum is an insensitive test for the diagnosis of non-small-cell lung cancer (NSCLC). We have recently demonstrated that polymerase chain reaction (PCR)-based molecular methods are more sensitive than cytologic analysis in diagnosing bladder cancer. In this study, we examined whether molecular assays could identify cancer cells in bronchoalveolar lavage (BAL) fluid. METHODS: Tumor-specific oncogene mutations, CpG-island methylation status, and microsatellite alterations in the DNA of cells in BAL fluid from 50 consecutive patients with resectable (stages I through IIIa) NSCLC were assessed by use of four PCR-based techniques. RESULTS: Of 50 tumors, 28 contained a p53 mutation, and the identical mutation was detected with a plaque hybridization assay in the BAL fluid of 39% (11 of 28) of the corresponding patients. Eight of 19 adenocarcinomas contained a K-ras mutation, and the identical mutation was detected with a mutation ligation assay in the BAL fluid of 50% (four of eight) of the corresponding patients. The p16 gene was methylated in 19 of 50 tumors, and methylated p16 alleles were detected in the BAL fluid of 63% (12 of 19) of the corresponding patients. Microsatellite instability in at least one marker was detected with a panel of 15 markers frequently altered in NSCLC in 23 of 50 tumors; the identical alteration was detected in the BAL fluid of 14% (three of 22) of the corresponding patients. When all four techniques were used, mutations or microsatellite instability was detected in the paired BAL fluid of 23 (53%) of the 43 patients with tumors carrying a genetic alteration. CONCLUSION: Although still limited by sensitivity, molecular diagnostic strategies can detect the presence of neoplastic cells in the proximal airway of patients with surgically resectable NSCLC.  (+info)

Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu. (6/7523)

In a trimodality treatment approach for stage III non-small cell lung cancer the prognostic impact of pretherapeutic p185neu assessment was evaluated. Fifty-four patients were admitted to chemotherapy followed by twice-daily radiation with concomittant low-dose chemotherapy and subsequent surgery. Immunohistochemical assessment of p185neu expression was performed in paraffin-embedded mediastinal lymph node metastases, by mediastinoscopy biopsy prior to therapy. Paraffin-embedded biopsies of mediastinal lymph node metastases were available in 33 cases. Seven out of eight patients with positive p185neu staining developed distant metastases, in contrast to seven out of 25 negative cases. Expression of p185neu in mediastinal lymph node metastases was a significant predictor for progression-free survival (p=0.047) and resulted mainly from significant differences in metastases-free survival (p185neu-positive versus p185neu-negative: median, 11 versus 19 months; 2- and 3-yr rates, 13% and 0% versus 40% and 32%; p=0.04). On the basis of these preliminary results it was concluded that further evaluation of p185neu expression in trials on neoadjuvant and adjuvant therapy is warranted. When the prognostic impact of p185neu in such trials with larger patient numbers is confirmed, this may contribute to the identification of stratification variables for future treatment approaches of non-small cell lung cancer.  (+info)

Combined modality therapy of lung cancer. (7/7523)

Combined modality therapy for lung cancer was first demonstrated to be successful in limited-stage small cell lung cancer. Concurrent administration of chemotherapy with chest and elective brain irradiation appears to produce the best results, with cisplatin/etoposide as the core chemotherapy. Using such programs, 2-year survival in the 40% range and 5-year survivals in excess of 20% may be expected, based on the results of multiple studies. Attempts to improve on these results through the use of altered schemes of chest irradiation or the delivery of high-dose consolidation chemotherapy are ongoing but to date have not been shown to affect survival significantly. We remain at a plateau in the effectiveness of combined modality therapy for small cell lung cancer, with little evidence that it impacts survival at all in extensive-stage disease. The incorporation of new agents in combination chemotherapy regimens, more "specific" immunotherapy directed at tumor-associated antigens, and the potential adjunctive use of broad-spectrum neuropeptide antagonists offer promise for the future. In non-small cell lung cancer, the sequential use of platinum-based chemotherapy and chest irradiation appears superior in survival to standard, daily fractionated radiation therapy used alone, with long-term survival increased from 5-10% to 15-20%. Concurrent administration of chemotherapy with cisplatin/etoposide and chest irradiation produces 2-year survival in the range of 30%, about twice that would be expected for radiation therapy alone, but has not been compared to it in the setting of a randomized trial. Low-dose cisplatin on a daily basis has been combined as a "sensitizer" with chest irradiation, producing initial results that appeared encouraging. However, these have not been reproduced in subsequent, randomized trials. Another approach to combined modalities has been to give chemotherapy or chemotherapy/radiation therapy as induction, followed by surgical resection, with or without subsequent additional treatment. Most patients (80-85%) can be resected, with encouraging survival at 2 and 3 years in the Southwest Oncology Group experience (37 and 26%, respectively). However, toxicity is greater, and such an approach is associated with an overall mortality risk in the range of 10%. A current intergroup study attempts to define the role of surgery in this setting. The major recent development that is likely to influence the future of combined modality therapy for this disease is the advent of multiple new chemotherapeutic agents, such as the taxanes, gemcitabine, vinorelbine, and the topoisomerase-I inhibitors, which have activity in stage IV disease. The immediate challenge is how to combine these agents with platinum analogues, radiation, and surgery. Aiding this process may be the use of molecular biological "markers" that may predict the chance of success or failure with a given systemic agent. The next decade is likely to see substantial improvements in the outcome of treatment for patients with stages I-III non-small cell lung cancer, based on the systemic exploration of combined modalities.  (+info)

The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. (8/7523)

AIMS: To investigate the expression of beta-catenin in non-small-cell lung cancer (NSCLC) and its clinical significance. METHODS: 101 patients were surgically treated for NSCLC by lobectomy or pneumectomy with systematic lymph node dissection. Follow up was available in all patients, ranging from 24 to 110 months. Immunostaining of tissue sections from primary tumours and (when present) their lymph node metastases was performed and evaluated using a monoclonal antibody against beta-catenin. Correlations were investigated between beta-catenin immunostaining in primary tumours and E-cadherin immunostaining (data available from a previous study), lymph node stage, and survival. RESULTS: There were significant correlations between scores for beta-catenin immunostaining and E-cadherin immunostaining in primary tumours (p = 0.007), and between the beta-catenin immunostaining score in primary tumours and in their lymph node metastases (p = 0.006). An inverse correlation was found between the beta-catenin immunostaining score in primary tumours and lymph node stage N0, N1, or N2 (p = 0.03). According to the Kaplan-Meier survival estimate, the level of beta-catenin expression in primary tumours was a statistically significant prognostic factor (p = 0.01). CONCLUSIONS: Reduced beta-catenin expression in surgically treated NSCLC is clearly associated with lymph node metastasis and an infavourable prognosis. The existence of a functional relation between E-cadherin and beta-catenin is supported by the results of this clinicopathological study.  (+info)

TY - JOUR. T1 - Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer. T2 - The eastern cooperative oncology group results. AU - Chang, A. Y.. AU - Kim, K.. AU - Glick, J.. AU - Anderson, T.. AU - Karp, D.. AU - Johnson, D.. PY - 1993/3/3. Y1 - 1993/3/3. N2 - Background: Patients with metastatic (stage IV) non-small-cell lung cancer usually have a poor prognosis and disease refractory to chemotherapy. Three new agents-taxol, merbarone, and piroxantrone-have shown promising antitumor treatment in vitro and in animals. Taxol is an antimicrotubular agent that interferes with mitosis during cell division. Merbarone, a conjugate of thiobarbituric acid and aniline, is a topoisomerase II inhibitor, which thus inhibits DNA synthesis and tumor growth. Piroxantrone, an anthracenedione derivative, is a DNA intercalating agent that has shown potent antitumor activity in animal studies. Purpose: Our randomized phase II study was designed to evaluate the efficacy and ...
1. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. The New England journal of medicine. 2006;355:983-91 2. Hubner RA, Riley RD, Billingham LJ, Popat S. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One. 2011;6:e25164 3. Allingham-Hawkins D, Lea A, Levine S. ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer. PLoS Curr. 2010;2:RRN1202 4. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T. et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007;98:1336-43 5. Malottki K, Popat S, Deeks JJ, Riley RD, Nicholson AG, Billingham L. Problems of variable biomarker evaluation in stratified medicine research-A case ...
Ionic channel activity is involved in fundamental cellular behaviour and participates in cancerous features such as proliferation, migration and invasion which in turn contribute to the metastatic process. In this study, we investigated the expression and role of voltage-gated sodium channels in non-small-cell lung cancer cell lines. Functional voltage-gated sodium channels expression was investigated in normal and non-small-cell lung cancer cell lines. The measurement, in patch-clamp conditions, of tetrodotoxin-inhibitable sodium currents indicated that the strongly metastatic cancerous cell lines H23, H460 and Calu-1 possess functional sodium channels while normal and weakly metastatic cell lines do not. While all the cell lines expressed mRNA for numerous sodium channel isoforms, only H23, H460 and Calu-1 cells had a 250 kDa protein corresponding to the functional channel. The other cell lines also had another protein of 230 kDa which is not addressed to the membrane and might act as a dominant
TY - JOUR. T1 - Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. AU - Perng, Reury Perng. AU - Chen, Yuh Min. AU - Ming-Liu, Jacqueline. AU - Tsai, Chun Ming. AU - Lin, Wei Chun. AU - Yang, Kuang Yao. AU - Whang-Peng, Jacqueline. N1 - Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 1997/1/1. Y1 - 1997/1/1. N2 - Purpose: A phase II randomized study was conducted to evaluate the efficacy and toxicity of gemcitabine (GEM) versus the combination of cisplatin and etoposide (EP) in Chinese patients with inoperable (stage III or IV) non-small-cell lung cancer (NSCLC). Patients and Methods: From March 1995 to February 1996, 53 patients were enrolled onto the study: 27 onto the GEM arm and 26 onto the EP arm. In the GEM arm, gemcitabine 1,250 mg/m2 was given as a 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle. In the EP arm, cisplatin 80 mg/m2 was given on ...
Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy
The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer. The vaccine regimen will consist of two fixed doses of recombinant DNA (pVAX/L523S) followed by two doses of recombinant adenovirus (Ad/L523S). The trial will evaluate the dose escalation of Ad/L523S through three cohorts of patients ...
Lung cancer is the leading cause of cancer-related mortality. Therapies against non-small cell lung cancer (NSCLC) are particularly needed, as this type of cancer is relatively insensitive to chemotherapy and radiation therapy. We recently identified GGTI compounds that are designed to block geranylgeranylation and membrane association of signaling proteins including the Rho family G-proteins. One of the GGTIs is P61A6 which inhibits proliferation of human cancer cells, causes cell cycle effects with G1 accumulation and exhibits tumor-suppressing effects with human pancreatic cancer xenografts. In this paper, we investigated effects of P61A6 on non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Three non-small cell lung cancer cell lines were used to test the ability of P61A6 to inhibit cell proliferation. Further characterization involved analyses of geranylgeranylation, membrane association and activation of RhoA, and anchorage-dependent and -independent growth, as well as cell cycle
OBJECTIVES:. I. To assess the safety and efficacy of a combination of vinorelbine and paclitaxel administered weekly to elderly patients with advanced non-small cell lung cancer.. II. To assess the response rate of a combination of vinorelbine and paclitaxel administered weekly to elderly patients with advanced non-small cell lung cancer.. III. To assess the quality of life of elderly patients with advanced non-small cell lung cancer during administration of weekly paclitaxel and vinorelbine.. OUTLINE:. Patients receive vinorelbine tartrate intravenously (IV) over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 5 years. ...
TY - JOUR. T1 - Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. T2 - Preliminary results comparing sequential phase II trials. AU - DeVore, R. F.. AU - Jagasia, M.. AU - Johnson, D. H.. PY - 1997/10/22. Y1 - 1997/10/22. N2 - Our group previously described the activity of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (given as a 24-hour infusion) in 51 patients with advanced non-small cell lung cancer. To facilitate outpatient administration, the regimen was modified to infuse paclitaxel over 1 hour. Between February 1995 and August 1996, 63 patients with advanced non-small cell lung cancer were accrued by the Vanderbilt Cancer Center and its affiliate network. The first four patients received paclitaxel 175 mg/ml2; all subsequent patients received paclitaxel 200 mg/m2. The carboplatin dose was determined using the Calvert formula, with a target area under the concentration-time curve of 6. ...
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.
TY - JOUR. T1 - Use of MicroRNA expression levels to predict outcomes in resected stage i non-small cell lung cancer. AU - Duncavage, Eric. AU - Goodgame, Boone. AU - Sezhiyan, Ananth. AU - Govindan, Ramaswamy. AU - Pfeifer, John. PY - 2010/11. Y1 - 2010/11. N2 - Background: Despite undergoing curative resection, nearly a third of patients with stage I non-small cell lung cancer (NSCLC) die of recurrent disease. There are no reliable clinical or molecular predictors of relapse in patients with resected stage I NSCLC. Identifying patients at risk for relapse after surgical resection is one of the important challenges today. MicroRNAs (miRNAs) regulate hundreds of genes central to maintaining a cancer phenotype. Methods: In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with ...
TY - JOUR. T1 - Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. AU - Gjerstorff, Morten F. AU - Pøhl, Mette. AU - Olsen, Karen E. AU - Ditzel, Henrik J. PY - 2013. Y1 - 2013. N2 - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown promising results. However, little is known about the expression of other cancer/testis antigens in NSCLC. In the present study the expression of cancer/testis antigens GAGE, NY-ESO-1 and SP17 was investigated in patients with completely resected, early stage, primary NSCLC.. AB - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen ...
Excerpt:. Patients with advanced non-small-cell lung cancer survive four months longer with fewer side effects on an immunotherapy drug called atezolizumab compared to chemotherapy, according to a phase 3 clinical trial published in The Lancet.. The trial enrolled 1225 advanced non-small-cell lung cancer patients who have no more treatment options, but this study used an early analysis of the first 850 patients from the trial. Half of the group were given atezolizumab and the other half were given docetaxel chemotherapy, which is the standard treatment for advanced non-small-cell lung cancer.. Patients given atezolizumab - a drug that blocks the programmed death ligand 1 (PD-L1) protein - survived for an average of 13.8 months, compared with 9.6 months for those on chemotherapy.. Go to full article.. ...
This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the g
PURPOSE OF REVIEW: The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, are effective as first-line treatment of advanced nonsmall cell lung cancer (NSCLC) harboring activating EGFR mutations (deletions in exon 19 and exon 21 L858R mutation). EGFR T790 M resistance mutation (EGFR T790 M) ultimately emerged in most of these patients. The second and third-generation EGFR-TKIs were designed to have more potent inhibition of EGFR and to overcome EGFR T790 M. This review describes the recent developments of these novel EGFR-TKIs.. RECENT FINDINGS: The second-generation EGFR-TKIs, afatinib and dacomitinib, irreversibly bind to the tyrosine kinase of EGFR and other ErbB-family members. Afatinib has been approved as first-line treatment of advanced NSCLC harboring activating EGFR mutations. Dacomitinib is under development. Third-generation EGFR-TKIs, AZD9291, CO-1686, and HM61713, inhibit both EGFR activating and resistance mutations, ...
This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previo
SOTIO presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer. The final analysis of the data confirmed the promising clinical efficacy of DCVAC/LuCa.
TY - JOUR. T1 - Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. AU - Zhu, Chang Qi. AU - Ding, Keyue. AU - Strumpf, Dan. AU - Weir, Barbara A.. AU - Meyerson, Matthew. AU - Pennell, Nathan. AU - Thomas, Roman K.. AU - Naoki, Katsuhiko. AU - Ladd-Acosta, Christine. AU - Liu, Ni. AU - Pintilie, Melania. AU - Der, Sandy. AU - Seymour, Lesley. AU - Jurisica, Igor. AU - Shepherd, Frances A.. AU - Tsao, Ming Sound. PY - 2010/10/10. Y1 - 2010/10/10. N2 - Purpose: The JBR.10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in early-stage non-small-cell lung cancer (NSCLC). We hypothesized that expression profiling may identify stage-independent subgroups who might benefit from ACT. Patients and Methods: Gene expression profiling was conducted on mRNA from 133 frozen JBR.10 tumor samples (62 observation [OBS], 71 ACT). The minimum gene set that was selected for the greatest separation of good and poor prognosis patient ...
TY - JOUR. T1 - Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. AU - Baldini, E.. AU - Tibaldi, C.. AU - Chella, A.. AU - Angeletti, C. A.. AU - Silvano, G.. AU - Andrei, A.. AU - Algeri, R.. AU - Conte, P. F.. PY - 1996/9. Y1 - 1996/9. N2 - Purpose: to evaluate the combination of vinorelbine, ifosfamide and cisplatin (VIP) in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Seventy-six untreated patients with stages IIIB-IV NSCLC; the chemotherapy regimen consisted of vinorelbine (25 mg/sqm on days 1 and 8), ifosfamide (3 g/sqm on day 1 with uroprotective mesna), and cisplatin (80 mg/sqm on day 1). The cycles were administered on an outpatient basis every 3 weeks. Results: Leukopenia was the most frequent toxicity: grades 3-4 neutropenia was observed in 26% of the cycles and 19 episodes of febrile neutropenia were reported in 289 evaluable courses. Filgrastim 5 μg/kg was administered in 27% of the ...
TY - JOUR. T1 - Patients preferences for treatment outcomes for advanced non-small cell lung cancer. T2 - A conjoint analysis. AU - Bridges, John F.P.. AU - Mohamed, Ateesha F.. AU - Finnern, Henrik W.. AU - Woehl, Anette. AU - Hauber, A. Brett. PY - 2012/7. Y1 - 2012/7. N2 - Background: Treatment decisions for advanced non-small cell lung cancer (NSCLC) are complex and require trade-offs between the benefits and risks experienced by patients. We evaluated the benefits that patients judged sufficient to compensate for the risks associated with therapy for NSCLC. Methods: Participants with a self-reported diagnosis of NSCLC (n= 100) were sampled from an online panel in the United Kingdom. Eligible and consenting participants then completed a self-administered online survey about their disease and their treatment preferences were assessed. This involved respondents choosing among systematically paired profiles that spanned eight attributes: progression-free survival [PFS], symptom severity, rash, ...
Effect of pulmonary wedge resection on Ia stage non-small cell lung cancer of elderly patients, its effect on serum anti-survivin antibody, Hsp90Ã Â and CEA levels, Run-hua Ti
TY - JOUR. T1 - Inhibitory effect of dihydroaustrasulfone alcohol on the migration of human non-small cell lung carcinoma A549 cells and the antitumor effect on a Lewis lung carcinoma-bearing tumor model in C57BL/6J mice. AU - Chen, Shuo Chueh. AU - Chien, Yi Chung. AU - Pan, Chun Hsu. AU - Sheu, Jyh Horng. AU - Chen, Chih Yi. AU - Wu, Chieh Hsi. PY - 2014/1. Y1 - 2014/1. N2 - There are many major causes of cancer death, including metastasis of cancer. Dihydroaustrasulfone alcohol, which is isolated from marine coral, has shown antioxidant activity, but has not been reported to have an anti-cancer effect. We first discovered that dihydroaustrasulfone alcohol provided a concentration-dependent inhibitory effect on the migration and motility of human non-small cell lung carcinoma (NSCLC) A549 cells by trans-well and wound healing assays. The results of a zymography assay and Western blot showed that dihydroaustrasulfone alcohol suppressed the activities and protein expression of matrix ...
This study will examine the effectiveness of a drug called Tarceva (erlotinib) giving prior to surgery in lung cancer patients. To be eligible for the study patients must have stage III Non-Small Cell Lung Cancer with EGFR mutation. Eligible patients will take Tarceva® (erlotinib) at a dose of 150 mg daily for approximately two months. After 2 months of erlotinib treatment, patients will have a PET/CT scan to determine whether they are responding to the treatment (i.e. whether or not the tumor shrunk or remains stable) or not. After the treatment patients will then be evaluated by a surgeon for surgical removal of the remaining tumor. Treatment after the surgery will be determined by the treating physician and it will be influenced by the response to treatment with Tarceva (erlotinib). A total of 55 patients with will take part in this multi-institution study.
TY - JOUR. T1 - Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations. T2 - The okayama lung cancer study group trial 1001. AU - Ichihara, Eiki. AU - Hotta, Katsuyuki. AU - Nogami, Naoyuki. AU - Kuyama, Shoichi. AU - Kishino, Daizo. AU - Fujii, Masanori. AU - Kozuki, Toshiyuki. AU - Tabata, Masahiro. AU - Harada, Daijiro. AU - Chikamori, Kenichi. AU - Aoe, Keisuke. AU - Ueoka, Hiroshi. AU - Hosokawa, Shinobu. AU - Bessho, Akihiro. AU - Hisamoto-Sato, Akiko. AU - Kubo, Toshio. AU - Oze, Isao. AU - Takigawa, Nagio. AU - Tanimoto, Mitsune. AU - Kiura, Katsuyuki. PY - 2015/3/30. Y1 - 2015/3/30. N2 - Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as ...
Sox2 and Oct4 are transcription factors with the characteristics of regulating self-renewal and differentiation of embryonic stem cell. The aim of this study was to detect the expression of Sox2 and Oct4 and analyze their clinical significance in human non-small-cell lung cancer (NSCLC). Expression of Sox2 and Oct4 were assayed in cancer tissues and their corresponding paracancerous tissues from 44 patients with NSCLC and 21 patients with benign tumors using immunohistochemistry, Western blot, reverse transcription polymerase chain reaction (RT-PCR). The correlation between the expression of Sox2 and Oct4 and tumor type, grade and prognosis and the utility of the two genes in discriminating between benign and malignant tumors were analyzed as well. The results showed that Sox2 and Oct4 positive staining was only seen in the nuclei of cancer cells but not in either the precancerous tissues or benign tumor tissues by immunohistochemistry (p | 0.01). Furthermore, in the lung cancer tissue, the positive
Tumour angiogenesis is an important factor for tumour growth and metastasis. Although some recent reports suggest that microvessel counts in non-small cell lung cancer are related to a poor disease outcome, the results were not conclusive and were not compared with other molecular prognostic markers. In the present study, the vascular grade was assessed in 107 (T1,2-N0,1) operable non-small cell lung carcinomas, using the JC70 monoclonal antibody to CD31. Three vascular grades were defined with appraisal by eye and by Chalkley counting: high (Chalkley score 7-12), medium (5-6), and low (2-4). There was a significant correlation between eye appraisal and Chalkley counting (P | 0.0001). Vascular grade was not related to histology, grade, proliferation index (Ki67), or EGFR or p53 expression. Tumours from younger patients had a higher grade of angiogenesis (P = 0.05). Apart from the vascular grade, none of the other factors examined was statistically related to lymph node metastasis (P | 0.0001). A
TY - JOUR. T1 - Chemoradiotherapy for poor-risk stage III non-small cell lung cancer.. AU - Lau, Derick H. AU - Ryu, J. K.. AU - Gandara, David R. PY - 1997/8. Y1 - 1997/8. N2 - Cisplatin-based chemoradiotherapy is becoming a standard treatment for patients with stage III non-small cell lung cancer (NSCLC). However, a significant proportion of patients with lung cancer also present with co-morbid conditions that indicate a poor prognosis and poor tolerance of treatment. We have completed a phase I/II study to evaluate the tolerability and efficacy of carboplatin-based chemoradiotherapy for patients with poor-risk stage III NSCLC. Twenty-four patients with stage IIIA/B NSCLC and concurrent medical conditions rendering them ineligible for cisplatin-based chemoradiotherapy protocols were treated with thoracic irradiation, 1.8 to 2 Gy daily to the primary tumor and regional lymph nodes, for a total dose of 61 Gy. Concurrently, patients received carboplatin 200 mg/m2/d intravenously on days 1, 3, 29, ...
TY - JOUR. T1 - Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non-small cell lung cancer. T2 - Evaluation of mass-like fibrosis. AU - Hayashi, Shinya. AU - Tanaka, Hidekazu. AU - Hoshi, Hiroaki. PY - 2015/3/1. Y1 - 2015/3/1. N2 - Background: This study aimed to evaluate stereotactic body radiation therapy (SBRT) in patients with stage I non-small cell lung cancer (NSCLC) in terms of radiation-induced changes and computed tomography (CT) features of local recurrence by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). Methods: From January 2006 to December 2012, 81 patients with NSCLC received SBRT. Follow-up consisted of non-contrast enhanced CT scans performed before and every four months after SBRT. In addition, 18F-FDG-PET/CT was conducted before SBRT for each patient, and one year later for each case suspected of recurrence. The CT findings were classified into two categories: mass-like fibrosis and others. The mass-like ...
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
125I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy:a comparison with best supportive care Jingjing Song* Xiaoxi Fan* Zhongwei Zhao* Minjiang Chen* Weiqian Chen, Fazong Wu, Dengke Zhang, Li Chen, Jianfei Tu, Jiansong Ji Department of Interventional Radiology, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, Zhejiang, Peoples Republic of China *These authors have contributed equally to this work Objectives: The objective of this study was to assess the efficacy of computed tomography (CT)-guided 125I brachytherapy alone in improving the survival and quality of life of patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) after one cycle of first-line chemotherapy.Patients and methods: Sixteen patients with locally advanced NSCLC were treated with CT-guided 125I brachytherapy after one cycle of first-line chemotherapy (group A). Sixteen
The purpose of this study was to compare patterns of failure between lobar resection (lobectomy or pneumonectomy) and stereotactic body radiation therapy (SBRT) for patients with clinical stage I non-small-cell lung cancer (NSCLC). From January
Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? Lung cancer;neutrophil to lymphocyte ratio;prognostic factors;C reactive protein; Background: Although many prognostic factors have been identified for lung cancers, new ones are needed to determine the course of the disease. Recently, a high neutrophil to lymphocyte ratio (NLR) prior to surgery or treatment has been shown to be an indicator of prognosis for cancer. The aim of this study was to investigate the value of NLR as a prognostic factor and the correlation between NLR and other probable clinical prognostic factors in non small cell lung cancer patients prior to treatment. Materials and Methods: Data of patients who were diagnosed with non-small cell lung cancer in our institution were retrospectively reviewed. Demographic and clinicopathologic characteristics were recorded. NLR was calculated before the application of any treatment. Results: A total of 299 patients, 270 (90%) males and 29 (10
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Wright on life chances with non small cell lung cancer: Stage 1 nsclc; surgical resection, appr70%5yrsurv stage2nsclc;surgery apprx. 30-35% 5 yr survival. for topic: Life Chances With Non Small Cell Lung Cancer
[130 Pages Report] Check for Discount on United States Non Small Cell Lung Cancer Therapeutics Industry 2016 Market Research Report report by QYResearch Group. The United States Non Small Cell Lung Cancer Therapeutics Industry...
Several factors, including regional UVB levels, vitamin D intake, skin pigmentation, sunlight exposure behaviors, and adiposity may influence in vivo vitamin D levels (21). Seasonal variation in 25(OH)D concentrations have been observed for residents in Boston (10-13), with inadequate vitamin D intake and winter season being independent predictors of hypovitaminosis D (13). We investigated the effects of season and vitamin D intake on NSCLC survival and found that both higher UVB exposure (patients who had surgery in summer) and higher vitamin D intake (diet and supplement) improved lung cancer survival. Patients who had surgery in summer with high vitamin D intake had a 3-fold better RFS and a 4-fold better OS than those with surgery in winter and low vitamin D intake, with all of the other patient groups falling between the two groups (Table 4; Fig. 2). In Cox proportional hazards models, we adjusted for the most important predictors of NSCLC prognosis, including age, gender, smoking status, ...
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non-small-cell lung cancer (NSCLC) who achieve radiographic regressions to the EGFR inhibitor gefitinib. One of these mutations, L858R (Leu→Arg), is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment. We characterized nine NSCLC cell lines (three isolated from patients with bronchioloalveolar carcinoma and six isolated from patients with adenocarcinoma) for their in vitro sensitivity to gefitinib. Of these, only H3255 (EGFRL858R) and H1666 (EGFRWT) are sensitive to gefitinib with IC50 values of 40 nmol/L and 2 μmol/L, respectively. We examined the effects of gefitinib on H3255 and cell lines containing wild-type EGFR that are either sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. Gefitinib treatment (1 μmol/L) leads to significant apoptosis accompanied by increased poly(ADP-ribose) ...
For patients with Stage III non-small cell lung cancer, prophylactic (preventive) radiation therapy to the brain reduces the risk of brain metastases but carries a risk of memory problems and doesnt appear to improve overall survival. These results were published in the Journal of Clinical Oncology.. Lung cancer remains the leading cause of cancer death in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.. One of the sites to which NSCLC can spread (metastasize) is the brain. Brain metastases can have a profound effect on survival and quality of life.. Prophylactic cranial irradiation (PCI) refers to the administration of radiation to the brain before brain metastases become apparent. The goal of PCI is the prevention of brain metastases. Previous studies have suggested that PCI can reduce the occurrence of brain metastases, but PCI has not become a part of routine NSCLC care because of concern about side effects and lack of evidence that ...
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults
An increasing number of chromosomal aberrations is being identified in solid tumors providing novel biomarkers for various types of cancer and new insights into the mechanisms of carcinogenesis. We applied next generation sequencing technique to analyze the transcriptome of the non-small cell lung carcinoma (NSCLC) cell line H2228 and discovered a fusion transcript composed of multiple exons of ALK (anaplastic lymphoma receptor tyrosine kinase) and PTPN3 (protein tyrosine phosphatase, nonreceptor Type 3). Detailed analysis of the genomic structure revealed that a portion of genomic region encompassing Exons 10 and 11 of ALK has been translocated into the intronic region between Exons 2 and 3 of PTPN3. The key net result appears to be the null mutation of one allele of PTPN3, a gene with tumor suppressor activity. Consistently, ectopic expression of PTPN3 in NSCLC cell lines led to inhibition of colony formation. Our study confirms the utility of next generation sequencing as a tool for the ...
The clinical significance of carbon-ion radiotherapy (CIRT) for octogenarians with locally advanced non-small-cell lung cancer (LA-NSCLC) remains unclear.
Disorders of cell adhesion are critical steps in cancer progression in which varieties of markers including cadherins are involved in.Btbd7 was found to inhibit E-cadherin expression in MDCK cells and play important roles during branching morphogenesis of embryonic salivary glands and lungs. However its function in malignant tumors is largely unknown. The aim of this study is to investigate the clinicopathological significance and possible function of Btbd7 in non-small cell lung cancer. Immunohistochemistry and Western blotting were used to investigate Btbd7 expression in non-small cell lung cancer and lung tissues. The clinicopathological association and the overall survival was analyzed. In vitro experiments were performed using siRNA to investigate the function of Btbd7 in lung cancer cells. Btbd7 expression was elevated in non-small cell lung cancer tissues compared to normal lung tissues. Increased Btbd7 expression was significantly associated with lymph node metastasis, reduced E-cadherin
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Among patients with metastatic non-small-cell lung cancer, early palliative care led to significant improvements in both quality of life and mood. As compared with patients receiving standard care, patients receiving early palliative care had less aggressive care at the end of life but longer surviv …
Introduction: A phase-II study was planned to test the effect of external beam radiotherapy in combination with endobronchial brachytherapy on the local control and survival of stage-III non-small cell lung cancer patients. Materials and methods: Thirty patients with stage-III non-small cell lung cancer have been treated with 60 Gy external beam radiotherapy and 3 x 5 Gy HDR endobronchial brachytherapy to control tumor and to prolong survival. Results: Therapy regimen was found to be very effective for the palliation of major symptoms, palliation rates were 42.8% for cough, 95.2% for hemoptysis, 88.2% for chest pain and 80.0% for dyspnea. There was a 76.7% tumor response (53.3% complete, 23.3% partial) verified by chest CT scans and bronchoscopy. However, median locoregional disease free survival was 9 +/- 4 months (95% Cl: 1-17) and it was only 9.6% at 5 years. Major side effects were radiation bronchitis (70.0%), esophagitis (6.6%) in the acute period and bronchial fibrosis (25%), esophagial ...
Objective: Lung cancer is the leading cause of cancer-related mortality worldwide. Disease stage still remains the best prognostic factor for patients with localized non-small cell lung cancer. The TNM staging system, however, does not address the heterogeneity of this disease. Sub-classification and identification of distinct prognostic sub-groups within each stage may allow the optimization of clinical trial design and potentially improve outcome. This is a retrospective pilot study, in which we attempt to identify genomic biomarkers predictive of recurrence in stage I lung cancer by analysing copy number (CN) data obtained by next-generation sequencing. Materials and Methods: Ninety eight patients with stage I NSCLC, who underwent elective radical surgery were identified from a tissue bank of 323 tumour samples. Their demographic and surgical data, including their recurrence status were collected and an extensive database compiled. The cases were split into two cohorts depending on their ...
TY - JOUR. T1 - Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy. T2 - A review of the national cancer data base. AU - Robinson, Cliff G.. AU - Patel, Aalok P.. AU - Bradley, Jeffrey D.. AU - DeWees, Todd. AU - Waqar, Saiama N.. AU - Morgensztern, Daniel. AU - Baggstrom, Maria Q.. AU - Govindan, Ramaswamy. AU - Bell, Jennifer M.. AU - Guthrie, Tracey J.. AU - Colditz, Graham A.. AU - Crabtree, Traves D.. AU - Kreisel, Daniel. AU - Krupnick, Alexander S.. AU - Patterson, G. Alexander. AU - Meyers, Bryan F.. AU - Puri, Varun. N1 - Publisher Copyright: © 2015 by American Society of Clinical Oncology. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.. PY - 2015/3/10. Y1 - 2015/3/10. N2 - Purpose To investigate the impact of modern postoperative radiotherapy (PORT) on overall survival (OS) for patients with N2 non-small-cell lung cancer (NSCLC) treated nationally with surgery and adjuvant chemotherapy. Patients and Methods ...
Lung cancer remains the major cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) account for at least 80% of all lung tumors and about 30% of them present with unresectable locally advanced disease at diagnosis (stage IIIA-IIIB) [1]. Until the mid 1980s standard treatment of patients with inoperable locally advanced NSCLC consisted of radiotherapy (RT) alone with a median survival time of 10 months[1]. From data about lung cancer population diagnosed in the second half of 1990s, overall survival at one and two years was estimated of 36% and 12% respectively[2].. Rates at 2 and 5 years of 15% and 5% respectively [3]. In attempts to improve the survival in these patients, chemotherapy was added to external beam irradiation. Several trials have been positive in favour of combined therapy [4-6]. More recently, other clinical trials have shown that, in selected patients (good performance status, age ≤ 75 years and minimal weight loss) concomitant platinum-based ...
Chemotherapy is one of the most important options for NSCLC and this therapeutic process is also a heavy burden for patients. Agents derived from various plants have been considered as potential alternative or auxiliary cure for cancer patients because research has shown that these therapeutic agents had no side effects, or at least the side effects were much more moderate compared with that of clinical first line chemotherapeutics. The anticancer effects of phloretin have been confirmed in various cancers (15-17), while its anti-cancer effects and underlying mechanisms on NSCLC is still uncertain. The aim of the present study was to evaluate the anticancer effects of phloretin on NSCLC cell lines and the results revealed that phloretin could exert anticancer effects on NSCLC cell lines and it also enhanced the anticancer effects of cisplatin.. In order to elucidate the effects of phloretin on cell vitality, MTT assay and flow cytometry were, respectively, carried out. MTT results showed that ...
Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer. We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR. For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; ...
Background: Tumor-infiltrating immune cells analyzed by immunohistochemistry are reported as alternative prognostic factors to supplement TNM staging in operable non-small cell lung cancer (NSCLC), but little is done by flow cytometry. Method: We established a protocol to analyze immune cells in tumor, distant lung (far from tumor) and peripheral blood mononuclear cells (PBMCs) by 8 color flow cytometry. 30 NSCLC patients with adenocarcinoma, squamous cell carcinoma and more uncommon histotypes were included and statistical analyses of cell subsets were performed. Results: We have identified the following tumor-infiltrating immune cells: CD45+ leukocytes, granulocytes, CD19+ B cells, CD4+ and CD8+ T cells with naïve/memory phenotype, CD56+CD16+ and CD56+CD16- NK cells, CD14+ macrophages, CD123+ plasmacytoid dendritic cells (pDCs), CD1c+ myeloid dendritic cells (mDCs) and CD141+ mDCs. There was an increase in leukocyte numbers in tumor compared with distant lung in adenocarcinoma. When expressed ...
TY - JOUR. T1 - Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. AU - Kawata, Toshio. AU - Higashimori, Mitsuo. AU - Itoh, Yohji. AU - Tomkinson, Helen. AU - Johnson, Martin G.. AU - Tang, Weifeng. AU - Nyberg, Fredrik. AU - Jiang, Haiyi. AU - Tanigawara, Yusuke. PY - 2019/5/1. Y1 - 2019/5/1. N2 - Purpose: A prospective, multicenter, large-scale cohort with a nested case-control study (NCT00252759) was conducted to identify and quantify risk factors for interstitial lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received gefitinib. This study reports the association between gefitinib exposure and the occurrence of ILD. Methods: A total of 1891 gefitinib plasma concentrations from 336 patients were measured after first dose, at steady state, and at time of ILD occurrence. Influences of demographic and pathophysiological factors on pharmacokinetics were investigated by non-linear mixed-effect modeling. ...
TY - JOUR. T1 - Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70. T2 - A multi-institutional case-control study. AU - Zimmermann, Matthias. AU - Nickl, Stefanie. AU - Lambers, Christopher. AU - Hacker, Stefan. AU - Mitterbauer, Andreas. AU - Hoetzenecker, Konrad. AU - Rozsas, Anita. AU - Ostoros, G.. AU - Laszlo, Viktoria. AU - Hofbauer, Helmut. AU - Renyi-Vamos, Ferenc. AU - Klepetko, Walter. AU - Döme, B.. AU - Ankersmit, Hendrik Jan. PY - 2012/7/11. Y1 - 2012/7/11. N2 - Introduction: Lung cancer represents a major healthcare problem. Accordingly, there is an urgent need to identify serum biomarkers for early diagnosis of lung pathology. We have recently described that patients with manifest COPD evidence elevated levels of heat shock proteins (HSPs). Based on these data, we speculated whether HSPs are also increased in patients with diagnosed lung cancer. Methods: Serum levels of HSP27, phospho-HSP27 (pHSP27) and HSP70 in patients with ...
San Antonio (TX), Bolton (MA). As originally published in International Clinical Trials, May 2015 - View PDF. In the fight against non-small cell lung cancer, all eyes have been on computed tomography imaging to aid early detection. But advances in the field are leading the oncology and radiology communities to consider novel measurement parameters and techniques to better assess tumour response.. Lung Cancer: Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined (colon, breast and pancreatic). In 2012, the estimate for new cases of lung cancer reached 226,160, with 164,770 deaths accounting for 27% of all cancer deaths. The five-year survival rate is low at 16%, often due to most patients having advanced disease at the time of presentation.. Non-small cell lung cancer (NSCLC) accounts for some 85% of lung cancer diagnoses. Fortunately for this subset of patients, surgery can often be curative, but only if ...
1. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1-19 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30 3. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10 4. Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H. et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3. Oncogene. 2018;37:4300-12 5. Dragnev K, You M Fau - Wang Y, Wang Y Fau - Lubet R, Lubet R. Lung cancer chemoprevention: difficulties, promise and potential agents?. Expert Opin Investig Drugs. 2013;22:35-47 6. Li Q, Zhang D, Chen X, He L, Li T, Xu X. et al. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Scientific reports. 2015;5:16082 7. Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X. et al. Continuous ...
TY - JOUR. T1 - MicroRNAs in non-small cell lung cancer. T2 - Gene regulation, impact on cancer cellular processes, and therapeutic potential. AU - Petrek, Hannah. AU - Yu, Ai Ming. PY - 2019/12/1. Y1 - 2019/12/1. N2 - Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of NSCLC biology is critical to improve the treatment of NSCLC. MicroRNAs (miRNAs or miRs) are a superfamily of genome-derived, small noncoding RNAs that govern posttranscriptional gene expression in cells. Functional miRNAs are commonly dysregulated in NSCLC, caused by genomic deletion, methylation, or altered processing, which may lead to the changes of many cancer-related pathways and processes, such as growth and death signaling, metabolism, angiogenesis, cell cycle, and epithelial to mesenchymal transition, as well as ...
The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI Thang Thanh Phan,1 Toan Trong Ho,1 Hue Thi Nguyen,1 Hang Thuy Nguyen,2 Thu Bich Tran,3 Son Truong Nguyen1 1Laboratory D Unit, Clinical Cancer Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam; 2Pathology Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam; 3Faculty of Biology and Biotechnology, University of Science, VNU-HCM, Ho Chi Minh City, Vietnam Purpose: To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). Patients and methods: One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either EGFR exon 19 deletion (E19del) or EGFR exon 21 L858R substitution mutation (L858R) were selected for this study. The blood cell count at different stages of treatment was used to calculate the inflammatory markers. The Kaplan-Meier
Celiac disease Ulcerative colitis Crohn's disease Hepatic cirrhosis Hepatocellular carcinoma Lung cancer, including small cell ... Mignogna MD, Fortuna G, Satriano AR (December 2008). "Small-cell lung cancer and necrolytic migratory erythema". The New ... Wilkinson DS (1973). "Necrolytic migratory erythema with carcinoma of the pancreas". Transactions of the St. John's Hospital ... swollen epidermal cells and necrosis of the superficial epidermis are most characteristic. Immunofluorescence is usually ...
Small cell lung carcinoma (SCLC) (FDA Oct 2007). As of 2016, experiments were under way for Neuroblastoma, Brainstem glioma, ... Topotecan is often given in combination with Paclitaxel as first line treatment for extensive-stage small-cell lung cancer. ... "FDA Rubber-Stamps APP Pharma's Generic Topotecan for Small Cell Lung and Cervical Cancers". 30 Nov 2010. DNA Topoisomerases and ... In addition, topotecan is experimentally treating Non-small cell lung cancer, Colorectal Cancer, Breast cancer, Non-Hodgkin ...
It was counterproductive in non-squamous non-small-cell lung carcinoma. International Nonproprietary Names for Pharmaceutical ... name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma ... Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28. " ...
... -containing drugs Gefitinib for treatment of non-small-cell lung carcinoma. Lapatinib for treatment of advanced- ... "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to ... Lapatinib eliminates the growth of breast cancer stem cells that cause tumor growth. The binding of lapatinib to the ATP- ... the cancer stem cell. Archived from the original on 2008-11-26. Nelson MH, Dolder CR (February 2006). "Lapatinib: a novel dual ...
... small-cell lung cancer, ovarian cancer). It has been granted Orphan drug status for Merkel cell carcinoma. It has reported ... "ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung ... encouraging Phase II results for small-cell lung cancer. Dimond PF (9 March 2010). "Antibody-Drug Conjugates Stage a Comeback ... It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a ...
"Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells". Lung Cancer. 50 (1): 19-24. doi: ... A case of suspected lung metastasis of pancreatic carcinoma with bronchorrhea similar to bronchioloalveolar carcinoma]". Nihon ... Shimura S, Takishima T (1994). "Bronchorrhea from diffuse lymphangitic metastasis of colon carcinoma to the lung". Chest. 105 ( ... Kitazaki T, Fukuda M, Soda H, Kohno S (2005). "Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; ...
Possible applications include non-small-cell lung carcinoma, hepatocellular carcinoma, and oesophageal cancer. In 2017, it was ... Tivantinib (ARQ197; by Arqule, Inc.) is an experimental small molecule anti-cancer drug. It is a bisindolylmaleimide that binds ... "ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko ... announced that a phase III clinical trial for advanced hepatocellular carcinoma had failed to meet the primary endpoint. " ...
In adults, most cases are associated with breast carcinoma or small-cell lung carcinoma. It is one of the few paraneoplastic ( ... and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes". Neurology. 62 (9): 1526-32. doi: ... possibly by expanding the memory B cell population. Studies have generally asserted that 70-80% of children with OMS will have ...
Lemmo, W; Tan, G (2016). "Prolonged Survival After Dichloroacetate Treatment of Non-Small-Cell Lung Carcinoma-Related ... cell death) of the malignant cells. In vitro work with DCA on neuroblastomas (which have fewer recognised mitochondrial ... These effects were not observed in non-tumor cells. Neuropathy has been a problem in some clinical trials with DCA causing them ... It can kill normal cells as well. A randomized controlled trial in children with congenital lactic acidosis found that while ...
He died of small cell lung carcinoma in Yerevan prison on October 8, 1940. "Sahak Torosyan - Wikipedia, the free encyclopedia ...
... not have non-superficial squamous-cell carcinoma or a mixture of both small-cell carcinoma and non-small-cell lung carcinoma or ... The PARAMOUNT trial is a clinical trial studying non-small-cell lung carcinoma (NSCLC). The trial was sponsored by Eli Lilly ... For patients with advanced non-small cell lung carcinoma (NSCLC), maintenance therapy is sometimes used when the initial ... participants must in the trial must have stage IIIB or IV nonsquamous non-small-cell lung carcinoma and have at least one ...
... of non-small-cell lung cancers; promoter hypermethylation of MLH1 occurs in 48% of squamous cell carcinomas; and promoter ... of non-small-cell lung cancers; promoter hypermetylation of ATM occurs in 47% ... In head and neck squamous cell carcinomas at least 15 DNA repair genes have frequently hypermethylated promoters; these genes ... Gagnon KT, Li L, Chu Y, Janowski BA, Corey DR (2014). "RNAi factors are present and active in human cell nuclei". Cell Rep. 6 ( ...
Its use was expanded to the treatment of squamous non-small-cell lung carcinoma in 2015. Medarex developed some of the first ... T cells attack cancer cells, but CTLA-4 and PD-1 act as "brakes" on the T cell's anti-cancer activities. The monoclonal ... releasing the T cell to attack cancer cells. Several monoclonal antibodies developed by Medarex have been approved for disease ... Medarex developed monoclonal antibodies to CTLA-4 and PD-1, which are proteins on the surface of T cells. ...
... died on December 12, 2008 at 13:05 pm of small cell lung carcinoma. He was a heavy smoker. Papadopoulos had ...
Speirs, Valerie (1989). The role of fibroblasts in the differentiation of human non-small cell lung carcinoma (PhD thesis). ... She worked with Ian Freshney on cell culture and became interested in how cell culture systems can be used to model disease. ... Valerie Speirs publications indexed by Google Scholar "Choosing the right cell line for your research". www.phe- ... PCR and response of in vitro cell cultures to steroid hormone". International Journal of Cancer. 72 (5): 714-719. doi:10.1002/( ...
Multiple system atrophy Multiple sclerosis Cancers Carcinomas Lung cancers (small-cell lung cancer, mesothelioma) ... SIADH was originally described in 1957 in two people with small-cell carcinoma of the lung. Anorexia Nausea Muscle aches ... all cells swell. Swelling of brain cells - cerebral edema - causes various neurological abnormalities which in acute and/or ... both inside and outside cells. The process occurs as follows: in some hypothalamic cells there are osmoreceptors which respond ...
In patients with small cell carcinoma of the lung, cancer cells in the lung can produce Hu proteins that are usually only found ... Because small cell lung cancer commonly occurs together with anti-Hu encephalitis, a diagnosis of small cell lung cancer ... The cancer-produced Hu proteins are found in nearly all small-cell lung carcinomas, 70 percent of neuroblastomas, and a small ... including spindle cell carcinoma of the sinus and a seminoma of the mediastinum. People with small cell carcinoma often have ...
... is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of ... "Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer". Journal of ... Cuban vaccine for non-small-cell lung cancer therapy". MEDICC Review. 12 (1): 17-23. doi:10.37757/MR2010.V12.N1.4. PMID ... based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients". Journal of Immune Based Therapies and Vaccines. ...
"A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma". Scientific Reports. 4: 4186 ... When 8 DNA repair genes were evaluated in non-small cell lung cancer (NSCLC) tumors, 42% were hypermethylated in the NEIL1 ... A screen of 145 DNA repair genes for aberrant promoter methylation was performed on head and neck squamous cell carcinoma ( ... that repairs damaged DNA throughout the cell cycle. It is responsible primarily for removing small, non-helix-distorting base ...
... including both non-small cell lung carcinoma and small cell lung carcinoma. Sarcoidosis Aspergilloma Tuberculosis ... Surgical option is usually the last resort and can involve removal of a lung lobe or removal of the entire lung. Cough ... Hemoptysis is the coughing up of blood or blood-stained mucus from the bronchi, larynx, trachea, or lungs. In other words, it ... Selective bronchial intubation can be used to collapse the lung that is bleeding. Also, endobronchial tamponade can be used. ...
... which is associated with small-cell carcinoma of the lungs. Anti-Ma2, associated with germ-cell tumours of the testis. Anti- ... Some of the rarer auto-antibodies (e.g., NMDAR) have no commercially available assay and can only be measured by a very small ... 100 cells/μl); elevated CSF protein (but usually ...
"Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non-Small-Cell Lung Carcinoma". ... diffuse large b-cell lymphoma and b-cells, acute myeloid leukemia, and lung cancer. Micro RNAs are important regulators of ... Kim, V. Narry; Han, Jinju; Siomi, Mikiko C. (2009). "Biogenesis of small RNAs in animals". Nature Reviews Molecular Cell ... The first analysis of small RNAs using miRNA-seq methods examined approximately 1.4 million small RNAs from the model plant ...
"Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer". Cancer. ... they slow the growth of cancer cells and induce cell cycle arrest. More specifically, these molecules suppress the protein Bcl- ... 2, which is a cancer-prone lymphoma protein, and induce cell death upon BRO (melanoma) cells. Since the 1970s, clinical trials ... The clinical trials showed between 10% and 16% decrease in lung cancer masses. At first, the United States was reluctant to ...
... that overlaps has-mir-196a2 has been found to be associated with non-small cell lung carcinoma. Lagos-Quintana M, Rauhut R, ... "Genetic variants of miRNA sequences and non-small cell lung cancer survival". J Clin Invest. 118 (7): 2600-8. doi:10.1172/ ... Kawasaki H, Taira K (2004). "MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells". Nucleic Acids ... J Cell Mol Med. 15 (1): 14-23. doi:10.1111/j.1582-4934.2010.01219.x. PMC 3276076. PMID 21091634. Scagnolari C, Zingariello P, ...
It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. https://searchusan. ... Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by ...
"A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer". ClinicalTrials.gov. August ... NRG Oncology Hepatocellular carcinoma (liver)-by NRG Oncology, Chang Gung Memorial Hospital, Loma Linda University Lung cancer- ... Liu Q (2015). "Lung Cancer Cell Line Screen Links Fanconi Anemia/BRCA Pathway Defects to Increased Relative Biological ... Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer". J ...
"Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma". British Journal ...
"Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma". ... "Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells". ... Cell. 130 (4): 624-637. doi:10.1016/j.cell.2007.06.013. PMC 2779720. PMID 17719541. "ACGT - Scientific Advisory Council - ... "Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells". Journal of Cell Biology. 185 (1 ...
... is also a tumor marker for small cell carcinoma of lung, gastric cancer, pancreatic cancer, and neuroblastoma. Gastrin ... It stimulates gastrin release from G cells. It activates three different G-protein-coupled receptors known as BBR1, -2, and -3 ... and their antagonists on proliferation of pancreatic cancer cell lines". Scandinavian Journal of Gastroenterology. 34 (12): ...
... specifically small-cell carcinoma, making LEMS a paraneoplastic syndrome. Of the people with small-cell lung cancer, 1-3% have ... Around 60% of those with LEMS have an underlying malignancy, most commonly small-cell lung cancer; it is therefore regarded as ... The antibodies found in LEMS associated with lung cancer also bind to calcium channels in the cancer cells, and it is presumed ... LEMS associated with lung cancer may be more severe. LEMS is often associated with lung cancer (50-70%), ...
Oral carcinoma[edit]. Patients after HSCT are at a higher risk for oral carcinoma. Post-HSCT oral cancer may have more ... Researchers have conducted small studies using non-myeloablative hematopoietic stem cell transplantation as a possible ... who have lost their stem cells after birth. Other conditions[13] treated with stem cell transplants include sickle-cell disease ... Peripheral blood stem cells[26] are now the most common source of stem cells for HSCT. They are collected from the blood ...
... , sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC). ... It has received regulatory approval for use as a treatment for non-small cell lung cancer,[6][4][7][8] although there is ... May 2012). "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of ... "Role of afatinib in the treatment of advanced lung squamous cell carcinoma". Clinical Pharmacology. 9: 147-157. doi:10.2147/ ...
Anaplastic cells have lost total control of their normal functions and many have deteriorated cell structures. Anaplastic cells ... However, a smaller tumor in an area such as Wernicke's area (small area responsible for language comprehension) can result in a ... Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic resonance imaging. ... Anaplastic astrocytoma, Astrocytoma, Central neurocytoma, Choroid plexus carcinoma, Choroid plexus papilloma, Choroid plexus ...
BaP was shown to cause genetic damage in lung cells that was identical to the damage observed in the DNA of most malignant lung ... Thus, in most cases, small amounts of BaP are metabolized prior to being passed into the blood.[citation needed] The lungs are ... In the 18th century a scrotal cancer of chimney sweepers, the chimney sweeps' carcinoma, was already known to be connected to ... "Lung cancer as consequence by Benzopyrene in smokers". Lung Cancer. Archived from the original on April 14, 2005. Retrieved ...
Non-small-cell lung cancer. Over-expression. 29%. Immunohistochemistry. [22]. Soft tissue sarcoma. Over-expression. 95%. ... Esophageal squamous cell cancer. Over-expression. 47%. Immunohistochemistry. [24]. Renal cell carcinoma. Under-expression. 100% ... of non-small cell lung cancers,[45] and 36% of colon cancers.[46] miR-34a is also generally under-expressed in primary ... "High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients". Br. J. ...
Small intestine cancer. *Small-cell carcinoma. *Soft-tissue sarcoma. *Spinal tumor. *Squamous cell carcinoma ...
... and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells". Molecular Pharmacology. 75 (1): 196-207. ... produced by carcinoma cells, acts through paracrine signaling on endothelial cells and through autocrine signaling on carcinoma ... Paracrine signaling is a form of cell-cell communication in which a cell produces a signal to induce changes in nearby cells, ... These T cells can then go on to perform effector functions such as macrophage activation, B cell activation, and cell-mediated ...
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. In: The New England Journal of Medicine. Band ... Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III ... Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer ... EAU guidelines on renal cell carcinoma: the 2010 update. In: European Urology. Band 58, 2010, S. 398-406, doi:10.1016/j.eururo. ...
The common house mold, Trichoderma longibrachiatum, produces small toxic peptides containing amino acids not found in common ... This affects in the cells action potential profile, as seen in cardiomyocytes, pneumocytes and neurons leading to conduction ... "National Heart, Lung, and Blood Institute. October 1, 2010. Retrieved January 15, 2014.. ... "Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment". Environmental Health Perspectives. 118 (6): ...
"Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". ... CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus ... Various types of CD30-positive T cell lymphomas[11]. *CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell ... "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor ...
Small-cell carcinoma. *Transitional cell carcinoma. Penis. *Carcinoma *Extramammary Paget's disease. *Bowen's disease ... Stage 3 seminoma is characterized by the presence of metastasis outside the retroperitoneum-the lungs in "good risk" cases or ... A seminoma is a germ cell tumor of the testicle or, more rarely, the mediastinum or other extra-gonadal locations. It is a ... Weidner N (February 1999). "Germ-cell tumors of the mediastinum". Seminars in Diagnostic Pathology. 16 (1): 42-50. PMID ...
Treatment of renal cell carcinoma with infliximab resulted in prolonged disease stabilization in certain patients. Etanercept ... negative regulation of branching involved in lung morphogenesis. • JNK cascade. • death-inducing signaling complex assembly. • ... positive regulation of heterotypic cell-cell adhesion. • negative regulation of mitotic cell cycle. • endothelial cell ... but it is produced also by a broad variety of cell types including lymphoid cells, mast cells, endothelial cells, cardiac ...
For example: non-melanoma skin cancer, head and neck cancer, breast cancer, non-small cell lung cancer, cervical cancer, anal ... 2005). "Cervix carcinoma". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium ... Targeting double-stranded breaks increases the probability that cells will undergo cell death. Cancer cells are generally less ... Fractionation allows normal cells time to recover, while tumor cells are generally less efficient in repair between fractions. ...
Virchow's cell, a macrophage in Hansen's disease. *Virchow's cell theory, omnis cellula e cellula - every living cell comes ... It is now believed that the Kaiser had hybrid verrucous carcinoma, a very rare form of verrucous carcinoma, and that Virchow ... Rudolph Leukart found that these tiny worms could develop into adult roundworms in the intestine of a dog. He correctly ... lung cancer. This has become known as Virchow's node and simultaneously Troisier's sign.[54][55] ...
squamous-cell carcinoma. *basal-cell carcinoma. *Merkel-cell carcinoma. *nevus sebaceous. *trichoepithelioma ... The word carbuncle is believed to have originated from the Latin: carbunculus, originally a small coal; diminutive of carbon-, ... The drainage of a lung abscess may be performed by positioning the patient in a way that enables the contents to be discharged ... The final structure of the abscess is an abscess wall, or capsule, that is formed by the adjacent healthy cells in an attempt ...
Originally started a laryngeal carcinoma strain, the cell line was contaminated and displaced by HeLa cells, and has now been ... The antigens of the anti-Sm antibodies are the core units of the small nuclear ribonucleoproteins (snRNPs), termed A to G, and ... They are associated with central nervous system involvement, kidney disease, lung fibrosis and pericarditis in SLE, but they ... T-cells and B-cells) and antigen presenting cells. These cells coordinate an immune response upon the detection of foreign ...
Small cell carcinoma is a very rare (1%[77]) type of prostate cancer that cannot be diagnosed using the PSA.[77][78] As of 2009 ... Further investigation with this substance revealed that it could interfere with the LT receptors in the lung carcinoma [38]. In ... Initially, small clumps of cancer cells remain confined to otherwise normal prostate glands, a condition known as carcinoma in ... "Small-cell carcinoma of the prostate". Journal of the Royal Society of Medicine. 90 (6): 340-1. PMC 1296316 . PMID 9227387.. ...
... and died of complications from metastatic lung cancer (metastatic small cell neuroendocrine carcinoma). He was transported to ...
Non-small-cell lung carcinoma. *Squamous-cell carcinoma. *Adenocarcinoma (Mucinous cystadenocarcinoma). *Large-cell lung ... Histologically, it forms clusters of goblet cells containing mucin with a minor admixture of Paneth cells and endocrine cells. ... Goblet cell carcinoid[edit]. Main article: Goblet cell carcinoid. This is considered to be a hybrid between an exocrine and ... The term 'crypt cell carcinoma' has been used for them, and though perhaps more accurate than considering them carcinoids, has ...
Alox5 gene knockout mice exhibit an increase in the lung tumor volume and liver metastasis of Lewis lung carcinoma cells that ... mead acid metabolizing cells produce relatively little LTB3 and are blocked from metabolizing arachidonic acid to LTB4. On the ... In skin, Langerhans cells strongly express ALOX5. Fibroblasts, smooth muscle cells and endothelial cells express low levels of ... mast cells, dendritic cells, and B-lymphocytes express ALOX5. Platelets, T cells, and erythrocytes are ALOX5-negative. ...
"Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies", Lancet, 341 (8836): 21-22, doi: ... The purpose of this clinical case demonstrates the aggressive nature of the neuroendocrine small cell carcinoma with rapid ... a case report of Neuroendocrine Small Cell Carcinoma of the Endometrium presenting as Paraneoplastic Cushing's Syndrome". Facts ... In the case of paraneoplastic Cushing's syndrome arising from a small cel carcinoma of the endometrium, paraneoplastic syndrome ...
... (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ... Large-cell lung carcinoma[edit]. Main article: Large-cell lung carcinoma. Large cell lung carcinoma (LCLC) is a heterogeneous ... using a uniform scheme for non-small cell lung carcinoma, small-cell lung carcinoma and broncho-pulmonary carcinoid tumors.[30] ... Non-Small Cell Lung Cancer at eMedicine *^ "What Is Non-Small Cell Lung Cancer?". www.cancer.org.. .mw-parser-output cite. ...
the salpingopalatine fold, a smaller fold, in front of the salpingopharyngeal fold, extending from the superior part of the ... and moisten air and conduct it into the lungs.[1]) The pharynx makes up the part of the throat situated immediately behind the ... the vertebrate pharynx is unique in that it gives rise to endoskeletal support through the contribution of neural crest cells.[ ... Nasopharyngeal carcinoma. *Pharyngeal aspiration. *Pharyngeal consonant. *Pharyngeal (disambiguation). *Saccopharynx, a genus ...
... used in the treatment of non-small-cell lung cancer[46][48][49]), vindesine, and vinflunine.[41] These drugs are cell cycle- ... "Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer". Clinical Medicine Insights: Oncology. 5: ... The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the ... M - mitosis; where the cell divides to produce two daughter cells that continue the cell cycle. ...
These can include the bones, lungs, liver, and/or brain.[16]. Treatment[edit]. Surgery has traditionally played a limited role ... IBC makes up only a small percentage of breast cancer cases (1-6% in the USA[4]). IBC is often diagnosed in younger women ... It is characterised by the presence of cancer cells in the subdermal lymphatics on skin biopsy. Consequently, IBC is always ... Ductal carcinoma in situ (DCIS): Paget's disease of the breast. *Comedocarcinoma. *Invasive ductal carcinoma (IDC) ...
Promoter hypermethylation of MLH1 occurs in 48% of non-small-cell lung cancer squamous cell carcinomas. Promoter ... of non-small-cell lung cancers. Promoter hypermetylation of ATM occurs in 47% of non-small-cell lung cancers. ... In head and neck squamous cell carcinomas at least 15 DNA repair genes have frequently hypermethylated promoters; these genes ... doi:10.1016/j.cell.2011.04.024. PMID 21620139.. *^ Saxonov S, Berg P, Brutlag DL (2006). "A genome-wide analysis of CpG ...
"Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer". Cancer Research. 71 (21): 6764-72. doi: ... Feb 2007). "Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions ... inhibit cell proliferation of endothelial cells. thrombospondin. inhibit cell migration, cell proliferation, cell adhesion and ... inhibit cell proliferation and induce apoptosis of endothelial cells. endostatin. inhibit cell migration, cell proliferation ...
... most often non-small-cell lung carcinoma (50 percent), small-cell lung carcinoma (25 percent), lymphoma, or metastasis, causing ... Dorsal root ganglion inflammation Small-cell lung cancer and, less often, cancer of the breast, colon or ovary may produce ... About 70 percent of breast and prostate cancer patients, and 40 percent of those with lung, kidney and thyroid cancers develop ... In breast, prostate or lung cancer, multiple myeloma and some other cancers, sudden onset limb or back pain may indicate ...
Micrograph of urethral cancer (urothelial cell carcinoma), a rare problem of the urethra. ... A small (1 or 2 cm) portion passing through the external urethral sphincter. This is the narrowest part of the urethra. It is ... It also serves as a passage for urine to flow.[1] Urine typically contains epithelial cells shed from the urinary tract. Urine ... The epithelium of the urethra starts off as transitional cells as it exits the bladder. Further along the urethra there are ...
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ... Large-cell lung carcinoma[edit]. Main article: Large-cell lung carcinoma. Large cell lung carcinoma (LCLC) is a heterogeneous ... using a uniform scheme for non-small cell lung carcinoma, small-cell lung carcinoma and broncho-pulmonary carcinoid tumors.[30] ... Non-Small Cell Lung Cancer at eMedicine *^ "What Is Non-Small Cell Lung Cancer?". www.cancer.org.. .mw-parser-output cite. ...
Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which ... 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. ... can also be associated with small cell lung cancer. Unlike extensive-stage small cell lung cancer, limited-stage small cell ... Unlike extensive-stage small cell lung cancer, limited-stage small cell lung cancer is potentially curable. In limited small ...
... Daniel J. Oh,1 Ellen Dinerman,1 Andrew H. Matthews,1 Abraham W. ... She was later diagnosed with small cell carcinoma of the lung. Conclusions. In this case report, we describe a critically ill ... However, its presence in solid tumors such as small cell carcinoma of the lung has been reported rarely [1-5]. Even fewer cases ... "Small cell lung cancer accompanied by lactic acidosis and syndrome of inappropriate secretion of antidiuretic hormone," Lung ...
Non-Small Cell Lung CarcinomaA Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better ... Non-Small Cell Lung CarcinomaTrial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer NCT00321308 ... Non-Small Cell Lung CarcinomaEvaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The ... Non-Small Cell Lung CarcinomaPH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line ...
Pfizer is currently recruiting for the NCT03052608 Non-Small-Cell Lung Carcinoma Cancer trial. Review trial description, ...
Diseases : Carcinoma: Non-Small-Cell Lung, Carcinoma: Small Cell Lung, Lung Cancer, Lung Cancer: Metastatic ... Diseases : Carcinoma: Small Cell Lung, Colon Cancer, Lung Cancer, Nasopharyngeal Cancer. Pharmacological Actions : Anti- ... Ganoderma is cytotoxic to both drug-sensitive and drug-resistant small-cell lung carcinoma cells and can reverse resistance to ... Diseases : Carcinoma: Small Cell Lung, Nicotine/Tobacco Toxicity Pharmacological Actions : Angiogenesis Inhibitors, Anti- ...
Diseases : Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Antineoplastic Agents, Apoptotic, Cell cycle ... Diseases : Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Anti-metastatic, Antiproliferative , Cell ... Diseases : Cancers: Drug Resistant, Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Apoptotic, Cell cycle ... Diseases : Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Anti-Inflammatory Agents, Anti-metastatic, ...
Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma. L C Rosenbaum, E A Neuwelt, H H ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY). The safety and scientific validity of this study is the ... Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res ...
... invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell ... lung carcinomas (NSCLC) and certain other human carcinomas. ... cultured cells from a non-small cell lung carcinoma, and (3) ... human lung carcinoma cells from pleural effusions or cultured cells from human non-small cell lung carcinoma, or cells from a ... Lung Carcinoma. Adeno 18/19. Squamous 8/10. Small Cell 2/6. Large Cell 2/2. Breast Carcinoma 13/16. Colon Carcinoma 9/9. ...
... little is known about how to prevent it. Recently this type of lung cance ... Because little is known about the actual cause of bronchoalveolar carcinoma, ... Non-Small Cell Lung Cancer. The most common type of lung cancer, non-small cell lung cancer (NSCLC) affects tens of thousands ... Continue Learning about Non-Small Cell Lung Cancer. Treating Non-Small Cell Lung Cancer with Immunotherapy ...
Carcinoma, Non-Small-Cell Lung. Carcinoma, Bronchogenic. Bronchial Neoplasms. Lung Neoplasms. Respiratory Tract Neoplasms. ... Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma. The safety and scientific validity of ... to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have progressed through ... Non Small Cell Lung Cancer Oligoprogressive Radiation: Local consolidative radiation therapy Drug: Standard of care radiation ...
It can inhibit the growth and induce morphological changes of NSCLC cells in gene transfection studies. To explore the ... gene is a recently identified tumor suppressor gene for human non-small cell lung carcinoma (NSCLC). ... DLC-1 tumor supressor gene induces apoptosis in human non-small cell lung carcinoma cells following a unique process of cell ... Carcinomas; Cell-growth; Microscopy; Genes; Tumorigens; Tumorigenesis; Gene-mutation; Liver-cells; Lung-cells ...
... to the process of tumor development was used in this study by examining the gene expression profile in human lung cancer cells ... Cell-function; Cell-growth; Cell-metabolism; Cell-transformation; Cellular-uptake; Lung-cancer; Lung-cells; Lung-disease; ... Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2 -deoxycytidine.. ... A cDNA array analysis was carried out on 5-aza-dC-treated and untreated non small cell lung cancer (NSCLC) cell line NCI-H522. ...
Learn more about Non-small Cell Lung Carcinoma from related diseases, pathways, genes and PTMs with the Novus Bioinformatics ... non-small cell lung cancer (disorder), carcinoma, non-small-cell lung, carcinoma non-small cell lung, carcinoma of lung. ... Non-small Cell Lung Carcinoma is also known as non-small cell lung carcinoma, nonsmall cell lung cancer, nsclc, ... Non-small Cell Lung Carcinoma: Disease Bioinformatics. Research of Non-small Cell Lung Carcinoma has been linked to Malignant ...
We tested the effects of Ganoderma on drug-sensitive (H69) and multi-drug resistant (VPA) human SCLC cells. Both cells showed ... Multidrug resistance is a major problem in small-cell lung cancer (SCLC). Ganoderma lucidum is a widely used herb in ... Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells Cancer Lett. 2009 May 18;277(2): ... Multidrug resistance is a major problem in small-cell lung cancer (SCLC). Ganoderma lucidum is a widely used herb in ...
... together with the large cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), and atypical carcinoid (AC) make a group ... cell morphology; small cell lung carcinoma; neuroendocrine carcinoma; non-small cell lung carcinoma; bronchoscopy; Kaplan Meier ... Small cell carcinoma of the lung (SCLC) together with the large cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), ... Miličić V, Prvulović I, Mišić M, Perić M, Samardžić S, Tomić K. Value of Cytology in Small Cell Lung Carcinoma Diagnostic - ...
Lung Neoplasms. Small Cell Lung Carcinoma. Carcinoma, Neuroendocrine. Carcinoma. Neoplasms, Glandular and Epithelial. Neoplasms ... SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma. The safety and scientific validity of this study is ... Part 1A is a dose escalation study in patients with small cell lung cancer or large cell neuroendocrine carcinoma with ... Genetics Home Reference related topics: Lung cancer Genetic and Rare Diseases Information Center resources: Small Cell Lung ...
Non-small Cell Carcinoma ) on www.antikoerper-online.... , Jetzt Produkt ABIN2456034 bestellen. ... Find and order tissues and products like this Lung Tissue Slide ( ... Non-small Cell Carcinoma ) Lung Tissue Slide (Non-small Cell ... Lung Produktmerkmale Preparation: The single tissue slides contain 4 μm sections of formalin-fixed, paraffin-embedded human ... Tissue or Cell type Lung Bestandteile Lung Tissue Slide (Non-small Cell Carcinoma ) ...
HomeIndustry SolutionsOncologyPreclinicalCell LinesNCI-H23: Human Non-Small Cell Lung Carcinoma ... Biologics SolutionsBiomarkersSmall Molecule SolutionsBiosimilars Development SolutionsCell & Gene Therapy Solutions ... Please note that cell lines are not for sale and unavailable for purchase from Covance.*** ... Cell LinesTumor ModelsCAR TIn VitroTumor SpotlightsPosters Choose Subcategory. Cell Lines. Tumor Models. CAR T. In Vitro. Tumor ...
... but these mutations have rarely been reported in small cell lung carcinoma (SCLC). Combined SCLC is rare, and the EGFR mutation ... receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung.. ... In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in ... In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide ...
... in non-small cell lung carcinomas. Lung Cancer. 61:163-169. 2008. View Article : Google Scholar : PubMed/NCBI ... The ALK fusion gene is a key oncogenic driver in a subset of patients with non-small cell lung carcinomas (NSCLCs) (1-5). EML4- ... Detection of CD74-ROS1 fusion transcripts in a non-small cell lung carcinoma (NSCLC). (A) cDNA derived from cancerous tissue of ... The recent discovery of fusion oncokinases in a subset of non-small cell lung carcinomas (NSCLCs) is of considerable clinical ...
... Cancer Immunol Immunother. ... from human non-small-cell lung carcinoma (NSCLC) specimens to synthesize type-1 and type-2 cytokines. ... Carcinoma, Non-Small-Cell Lung / metabolism* * Carcinoma, Non-Small-Cell Lung / pathology ... were also detected in a small percentage of infiltrating cells. Following activation with phorbol 12-myristate 13-acetate + ...
... in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance ... Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas. May 5, 2010. ScienceBlog.com ... in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance ... Expression rate also associated more so with adenocarcinoma histology (39 percent) than in squamous cell carcinoma histology ( ...
Criteria in Patients With Stage IV Non-small Cell Lung Carcinoma (NSCLC) ... Patients must have progressive non-small cell lung cancer (NSCLC). - No more than 2 prior systemic agent or regimen at least 28 ... A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung ... A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung ...
... and alternating resting potentials were measured in cells from a continuously cultured small cell carcinoma of the lung. Spike ... Calcium spike electrogenesis and other electrical activity in continuously cultured small cell carcinoma of the lung ... Calcium spike electrogenesis and other electrical activity in continuously cultured small cell carcinoma of the lung ... Calcium spike electrogenesis and other electrical activity in continuously cultured small cell carcinoma of the lung ...
Survival of non small cell lung carcinoma patients with malignant pleural effusions. Umut Sabri Kasapoglu, Sibel Arinc, Armagan ... Survival of non small cell lung carcinoma patients with malignant pleural effusions ... Survival of non small cell lung carcinoma patients with malignant pleural effusions ... Survival of non small cell lung carcinoma patients with malignant pleural effusions ...
Codeletion of p15 and p16 Genes in Primary Non-Small Cell Lung Carcinoma. Sheng Xiao, Daizong Li, Joseph M. Corson, Jan Vijg ... Chromosome band 9p21 is deleted frequently in non-small cell lung carcinoma (NSCLC), and the p15 and p16 cyclin-dependent ... Codeletion of p15 and p16 Genes in Primary Non-Small Cell Lung Carcinoma ... Codeletion of p15 and p16 Genes in Primary Non-Small Cell Lung Carcinoma ...
  • Non-small-cell lung carcinoma ( NSCLC ) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). (wikipedia.org)
  • NSCLC accounts for about 85% of all lung cancers. (wikipedia.org)
  • The most common types of NSCLC are squamous cell carcinoma , large cell carcinoma , and adenocarcinoma , but there are several other types that occur less frequently. (wikipedia.org)
  • [5] Non-squamous cell carcinoma almost occupy the half of NSCLC. (wikipedia.org)
  • Lung cancer in people who have never smoked is almost universally NSCLC, with a sizeable majority being adenocarcinoma. (wikipedia.org)
  • On relatively rare occasions, malignant lung tumors are found to contain components of both SCLC and NSCLC. (wikipedia.org)
  • LCLC's have typically comprised around 10% of all NSCLC in the past, although newer diagnostic techniques seem to be reducing the incidence of diagnosis of "classic" LCLC in favor of more poorly differentiated squamous cell carcinomas and adenocarcinomas. (wikipedia.org)
  • AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC). (pfizer.com)
  • Patients with mixed NSCLC with predominantly squamous cell carcinoma should be classified as squamous and thus do not qualify for this study. (pfizer.com)
  • NSCLC that cannot be classified as one of the eligible histologies (adenocarcinoma, large cell or bronchioalveolar). (pfizer.com)
  • The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. (freepatentsonline.com)
  • The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. (freepatentsonline.com)
  • The most common type of lung cancer, non-small cell lung cancer (NSCLC) affects tens of thousands of people each year. (sharecare.com)
  • With three primary types of NSCLC, this disease accounts for about 80% of all lung cancer, the deadliest type of cancer in the U.S. among both men and women. (sharecare.com)
  • Adenocarcinoma, the most common form of NSCLC, typically develops in the outer portion of our lungs. (sharecare.com)
  • The deleted in liver cancer (DLC-1) gene is a recently identified tumor suppressor gene for human non-small cell lung carcinoma (NSCLC). (cdc.gov)
  • It can inhibit the growth and induce morphological changes of NSCLC cells in gene transfection studies. (cdc.gov)
  • A cDNA array analysis was carried out on 5-aza-dC-treated and untreated non small cell lung cancer (NSCLC) cell line NCI-H522. (cdc.gov)
  • Among them, downregulation of tyrosine protein kinase ABL2 (ABL2) gene and upregulation of hint/protein kinase C inhibitor 1 (Hint/PKCI-1), DVL1, TIMP-1, and TRP-1 genes were found in expanded observations in two or three of five 5-aza-dC-treated NSCLC cell lines. (cdc.gov)
  • Among these genes, we found that cDNA transfer of Hint/PKCI-1 resulted in a significant in vitro growth inhibition in two cell lines exhibiting 5-aza-dC-induced upregulation of Hint/PKCI-1 and significantly reduced in vivo tumorigenicity of one NSCLC cell line. (cdc.gov)
  • Non-small Cell Lung Carcinoma is also known as non-small cell lung carcinoma, nonsmall cell lung cancer, nsclc, non-small cell lung cancer (disorder), carcinoma, non-small-cell lung, carcinoma non-small cell lung, carcinoma of lung. (novusbio.com)
  • Recently, crizotinib, a small molecule inhibitor of ALK, was shown to selectively inhibit the growth of ALK-positive NSCLC ( 6 - 8 ), indicating that a subclass of NSCLC patients are likely to benefit clinically from an ALK inhibitor. (spandidos-publications.com)
  • However, since the incidence of ROS1 or RET fusions is less than that of ALK fusions in NSCLC, only a small number of NSCLC patients with ROS1 or RET fusions has thus far been identified. (spandidos-publications.com)
  • The purpose of this work was to assess the capacity of tumor-infiltrating leukocytes (TIL) from human non-small-cell lung carcinoma (NSCLC) specimens to synthesize type-1 and type-2 cytokines. (nih.gov)
  • The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance. (scienceblog.com)
  • NSCLC (includes squamous, large cell or adenocarcinoma). (knowcancer.com)
  • Chromosome band 9p21 is deleted frequently in non-small cell lung carcinoma (NSCLC), and the p15 and p16 cyclin-dependent kinase-4 inhibitor genes map within this deletion region. (aacrjournals.org)
  • Recent studies demonstrated deletion of p15 and p16 in NSCLC metastases and cell lines, suggesting a role for these genes in NSCLC progression. (aacrjournals.org)
  • Recent data suggest that the tumour, node, metastasis classification traditionally reserved for the staging of nonsmall cell lung cancer (NSCLC) can also be applied for the staging of SCLC 3 . (ersjournals.com)
  • in small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). (ersjournals.com)
  • Retinoblastoma (RB) protein expression was examined in paraffin and frozen tissue sections of 36 primary non-small cell lung carcinomas (NSCLC) using immunohistochemistry with confirmation by direct Western blotting. (aacrjournals.org)
  • Parathyroid hormone-related protein (PTHrP) is commonly expressed in non-small cell lung carcinomas (NSCLC). (aacrjournals.org)
  • Because roughly two thirds of non-small cell lung cancers (NSCLC) express PTHrP regardless of histology ( 20 ), the protein could be important in the pathophysiology of the disease beyond its role in causing hypercalcemia. (aacrjournals.org)
  • Hence, the goal of this project was to conduct a large patient study to determine whether survival of patients with NSCLC varied based on tumor PTHrP expression and to examine the influence of PTHrP with other factors known to affect patient life span in lung cancer. (aacrjournals.org)
  • The possible involvement of estrogen receptors (ERs) and testicular orphan nuclear receptors (TRs) in human non-small cell lung carcinoma (NSCLC) has been suggested, but their precise roles and their relationship remain largely unknown. (spandidos-publications.com)
  • We used tissue microarrays including NSCLC tissues (n=154) and negative controls (n=14) to examine the expression of TRA16 and ERβ, and in vitro reporter gene assays, the mammalian two-hybrid method and immunoprecipitation in Cos-1 cells to investigate the relationships among TRA16, ERβ and TR2. (spandidos-publications.com)
  • Our findings demonstrate that TRA16 could be a promising diagnostic and prognostic biomarker in NSCLC, and promotes cancer cell growth through activation of the ERβ pathway by interacting with ERβ and TR2. (spandidos-publications.com)
  • Niikawa et al first reported that intratumoral estradiol (an activator of ERβ) concentration was significantly higher than that of corresponding non-neoplastic lung tissues, and positively associated with tumor size and Ki-67 labeling index (LI) in ER-positive NSCLC tissues ( 8 ). (spandidos-publications.com)
  • To identify the pattern of IRAK-1 protein expression in non-small cell lung carcinoma (NSCLC) and corresponding preneoplastic lesions. (pubmedcentralcanada.ca)
  • IRAK-1 is frequently expressed in NSCLC tissue specimens, and this expression is an early phenomenon in the sequential development of lung cancer. (pubmedcentralcanada.ca)
  • the two most common NSCLC histologic types are squamous cell carcinoma (SCC) and adenocarcinoma (ADCA) ( 2 ). (pubmedcentralcanada.ca)
  • Both NSCLC histologic types are believed to arise after a sequential progression of premalignant lesions, which include bronchial squamous metaplasias and dysplasias for squamous cell carcinoma, and peripheral atypical alveolar hyperplasias (AAH) for a subset of adenocarcinomas ( 3 ). (pubmedcentralcanada.ca)
  • Attending the seminar, Dr Basma M'Barek, Hy Vong Cancer Care Centre from FV Hospital, shared her experiences on the topic Optimizing When Using Osimertinib in Treating Non-Small-Cell Lung Carcinoma NSCLC & Sharing Treated Cases . (fvhospital.com)
  • our earlier studies had shown that reported ID1 is induced by nicotine or EGF stimulation of non-small cell lung cancer (NSCLC) cells and its down regulation abrogates cell proliferation, invasion and migration. (springer.com)
  • A microarray analysis was done on two different NSCLC cell lines (A549 and H1650) that were transfected with a siRNA to ID1 or a control, non-targeting siRNA. (springer.com)
  • STMN3 and GSPT1 were found to facilitate the proliferation, invasion and migration of NSCLC cells in response to nAChR activation. (springer.com)
  • Compared to non-small cell lung cancer (NSCLC), SCLC is generally more aggressive, with decreased doubling times and faster growth rates. (biomedcentral.com)
  • Aberrant signalling of receptor tyrosine kinases (RTKs), such as c-Met, the receptor for hepatocyte growth factor (HGF), has been implicated in the oncogenesis of various tumours including non-small cell lung carcinoma (NSCLC). (biologists.org)
  • This finding was confirmed in several NSCLC cell lines as well as in HeLa cells. (biologists.org)
  • However, the immunological profile of non-small cell lung carcinoma (NSCLC) treated with neoadjuvant chemotherapy (NCT) is not yet fully characterized, and it may be therapeutically important. (deepdyve.com)
  • The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown promising results. (biomedcentral.com)
  • However, little is known about the expression of other cancer/testis antigens in NSCLC. (biomedcentral.com)
  • Tumor biopsies from normal lung tissue and from a large cohort (n = 169) of NSCLC patients were examined for GAGE, NY-ESO-1 and SP17 protein expression by immunohistochemical analysis. (biomedcentral.com)
  • Non-small cell lung cancer (NSCLC) accounts for more than 85% of new cases of lung cancer, which is the leading cause of cancer deaths worldwide [ 7 ], highlighting the need for novel therapeutic strategies for treatment of this disease. (biomedcentral.com)
  • Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. (ersjournals.com)
  • Until the arrival of pemetrexed, a relatively simple distinction between small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC) was sufficient to guide systemic treatment, and a meta-analysis of four different platinum doublets showed that none offered a significant advantage over the others in the treatment of advanced NSCLC [ 1 ]. (ersjournals.com)
  • As a result, the pathological diagnosis of lung cancer has become a multistep process, beginning with morphology and immunohistochemistry (IHC) to discriminate benign from malignant process, metastases from primary lung cancer and small cell lung carcinoma and NSCLC. (ersjournals.com)
  • BACKGROUND: Non-small cell lung carcinoma (NSCLC) is a complex malignancy that owing to its heterogeneity and poor prognosis poses many challenges to diagnosis, prognosis and patient treatment. (ox.ac.uk)
  • Here we present a genome-wide DNA methylation analysis of NSCLC samples and paired lung tissues, where we combine MethylCap and next generation sequencing (MethylCap-seq) to provide comprehensive DNA methylation maps of the tumor and paired lung samples. (ox.ac.uk)
  • We also identified DMRs that were specific to two of the major subtypes of NSCLC, adenocarcinomas and squamous cell carcinomas. (ox.ac.uk)
  • CONCLUSIONS: Collectively, we provide a resource containing genome-wide DNA methylation maps of NSCLC and their paired lung tissues, and comprehensive lists of known and novel DMRs and associated genes in NSCLC. (ox.ac.uk)
  • Non-small-cell lung carcinomas (NSCLC) are the most common form and account for around 85 - 90% of total lung cancers. (images.md)
  • ALK gene rearrangements in advanced non-small cell lung carcinomas (NSCLC) are an indication for targeted therapy with crizotinib. (elsevier.com)
  • The aim of this study was to perform a systematic review of the MEDLINE literature on the prognostic significance of these histopathological markers in patients with non-small cell lung carcinoma (NSCLC). (springeropen.com)
  • Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. (nih.gov)
  • Recent large scale genomic studies from the Clinical Lung Cancer Genome Project have identified different driver gene mutations in the subtypes of non-small cell lung carcinoma (NSCLC). (nih.gov)
  • These findings not only lead to remarkable progress in targeted therapies for lung cancer patients, but also provide fundamental knowledge for the subclassification of NSCLC. (nih.gov)
  • These guidelines emphasize: (1) the subclassification of NSCLC, (2) the critical role of molecular characterization of tumors for targeted therapy, (3) the unique terminology for subclassifying NSCLC using small biopsy specimens, and (4) the utility of IHC biomarkers in the accurate diagnosis and subclassification of lung cancer. (nih.gov)
  • In this review, we summarize the current WHO guidelines for the classification of lung cancer, discuss advancements of targeted therapy and immunotherapy, and address the utility and limitation of immunomarkers in the subclassification of NSCLC, as well as the prospective future of the field. (nih.gov)
  • To study expression of Anaplastic Lymphoma Kinase (ALK)and Epidermal Growth Factor Receptor (EGFR) mutations in patients of Non-Small Cell Lung Cancer NSCLC, that are the targets for specific ALK inhibitors and EGFR tyrosine kinase inhibitors. (jcdr.net)
  • Total 69 cases of histologically diagnosed NSCLC were examined retrospectively for immunohistochemical expression of EGFR and ALK, along with positive control of normal placental tissue and anaplastic large cell lymphoma respectively. (jcdr.net)
  • OBJECTIVE To study the association between HAb18G expression, tumor parameters, metastatic potential and prognosis in non-small cell lung carcinoma (NSCLC). (semanticscholar.org)
  • EGF-stimulated EGFR phosphorylation induced S100A2 expression and further activated E1A expression of Ad/SA, which was restored by EGFR signal inhibition in a concentration-dependent manner in non-small-cell lung carcinoma (NSCLC). (elsevier.com)
  • Patients treated with nivolumab for advanced non-small cell lung carcinoma (NSCLC) had a better survival rate at five years than those who received chemotherapy, a follow-up trial has shown [1] . (pharmaceutical-journal.com)
  • Checkmate 017 and [Checkmate] 057 are the first phase III trials to report five-year outcomes for a [programmed cell-death protein 1 (PD-1)] inhibitor in previously treated advanced NSCLC," said Scott Gettinger, professor of internal at Yale Comprehensive Cancer Center, Connecticut, and lead author of the study. (pharmaceutical-journal.com)
  • The aim of this study is to assess the effects of the two single nucleotide polymorphisms (SNPs), the guanine insertion polymorphism in the MMP1 promoter and the adenosine insertion polymorphism in the MMP3 promoter, on risk of the development and lymphatic metastasis of non-small cell lung carcinoma (NSCLC). (cdc.gov)
  • Aims: To investigate the distribution of epidermal growth factor receptor (EGFR) mutations, and explore any relationships with clinical characteristics in non-small-cell lung carcinoma (NSCLC) patients. (waocp.org)
  • There are two different types of lung cancer to be distinguished: the small-cell lung cancer (SCLC) and the non-small-cell lung cancer (NSCLC). (therapyselect.de)
  • Non-small-cell lung cancer (NSCLC) represents most of lung cancers, is often diagnosed at an advanced metastatic stage. (nature.com)
  • The expression of B cell receptor-associated protein 31 (BCAP31), calreticulin, glucose-regulated protein 78, and glucose-regulated protein 94 were analyzed using immunohistochemical staining of 360 NSCLC patients. (nature.com)
  • Then, three NSCLC cell lines were transfected to observe behavior changes BCAP31 caused, we found the fluctuation of BCAP31 significantly influenced the migration, invasion of NSCLC cells. (nature.com)
  • Non-small-cell lung cancer (NSCLC) contributes to 85% of lung cancer cases. (nature.com)
  • Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC). (wikipedia.org)
  • Squamous-cell carcinoma of the lung is strongly associated with tobacco smoking, more than any other forms of NSCLC. (wikipedia.org)
  • Some alterations such as the ones affecting TP53 and CDKN2A are shared by lung SCC and the other most common type of NSCLC, lung adenocarcinoma. (wikipedia.org)
  • Adenocarcinoma of the lung is currently the most common type of lung cancer in "never smokers" (lifelong non-smokers). (wikipedia.org)
  • Historically, adenocarcinoma was more often seen peripherally in the lungs than small cell lung cancer and squamous cell lung cancer, both of which tended to be more often centrally located. (wikipedia.org)
  • It is closely correlated with a history of tobacco smoking , more so than most other types of lung cancer . (wikipedia.org)
  • [13] LCLC is, in effect, a "diagnosis of exclusion", in that the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. (wikipedia.org)
  • Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a radiation portal. (wikipedia.org)
  • This generally includes cancer to one side of the lung and those might have reached the lymph nodes on the same side of the lung. (wikipedia.org)
  • 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. (wikipedia.org)
  • Nervous system problems, Cushing syndrome and SIADH (syndrome of inappropriate anti-diuretic hormone) can also be associated with small cell lung cancer. (wikipedia.org)
  • Unlike extensive-stage small cell lung cancer, limited-stage small cell lung carcinoma is potentially curable. (wikipedia.org)
  • Small cell lung cancer is often treated as a systematic disease due to its tendency for early dissemination, thus, instead of the traditional TNM staging system, the Veterans' Administration Lung Study Group (VALSG) introduced a simplified 2-stage system in 1950s to divide small cell lung cancer into limited stage and extensive stage. (wikipedia.org)
  • Variability in categorising small-cell lung cancer as limited or extensive occurs with reference to the extent of pleural effusion and nodal stations involvement. (wikipedia.org)
  • Imaging tests are often the first diagnostic step if a patient reports symptom that may be suggestive of lung cancer. (wikipedia.org)
  • If abnormality is present, a computed tomography (CT) scan is frequently ordered to reveal the size, shape, and position of any lung tumour and can help locate enlarged lymph nodes that might contain cancer metastasised from the lung origin. (wikipedia.org)
  • Most patients with limited-stage small cell lung cancer will receive a CT scan of the chest and abdomen to search for abnormality within the lungs and lymph nodes, as well as abnormal areas in more distal organs such as adrenal glands and liver that might arise from the metastasis of lung cancer. (wikipedia.org)
  • For patient with limited-stage small cell lung cancer, a positron emission tomography (PET) scan is a useful diagnostic tool to investigate the extent of lymph node involvements, which can help determine treatment options. (wikipedia.org)
  • Though results of imaging test might be suggestive of lung cancer, the actual diagnosis is made by investigating the lung cells under the microscope via lab tests. (wikipedia.org)
  • Small cell or carcinoid lung cancer patients are also ineligible. (pfizer.com)
  • Serum IL-23 levels are elevated in lung cancer patients. (greenmedinfo.com)
  • The median survival time of patients in the deuterium depleted water consuming group was 2-4 times longer than it is generally observed in lung cancer patients. (greenmedinfo.com)
  • Siberian ginseng extracts had atiproliferative activity on various cancer and normal cell lines. (greenmedinfo.com)
  • Spontaneous regression of metastatic squamous cell lung cancer. (greenmedinfo.com)
  • Citrus reticulata peel oil inhibits non-small cell lung cancer cell proliferation. (greenmedinfo.com)
  • Shikonin could be a novel therapeutic strategy against non-small cell lung cancer. (greenmedinfo.com)
  • Recently this type of lung cancer has been increasingly diagnosed in non-smoking women as well as people with Asian descent. (sharecare.com)
  • However, there are several preventable factors that are known play a role in developing other types of lung cancer. (sharecare.com)
  • In order to prevent lung cancer, doctors usually recommend that people avoid cigarette smoke (both first-hand and second-hand), exercise frequently, and eat a healthy diet. (sharecare.com)
  • Immunotherapies are a category of cancer drugs that work by helping the body's immune system identify and destroy cancer cells. (sharecare.com)
  • What are the different types of non-small cell lung cancer? (sharecare.com)
  • How can I prepare for an appointment for non-small cell lung cancer? (sharecare.com)
  • Although smoking is the primary cause of lung cancer, other risk factors include exposure to radon gas and asbestos. (sharecare.com)
  • Previous radiation therapy and a family or personal history of lung cancer also increases your risk. (sharecare.com)
  • A new approach in identifying alterations of genes that might be relevant to the process of tumor development was used in this study by examining the gene expression profile in human lung cancer cells exposed to 5-aza-2'-deoxycytidine (5-aza-dC). (cdc.gov)
  • Multidrug resistance is a major problem in small-cell lung cancer (SCLC). (nih.gov)
  • Median survival in the group of patients with histologically confirmed small cell cancer was 238 days, for women 250 days, and for men 237 days. (srce.hr)
  • This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). (clinicaltrials.gov)
  • Part 1A is a dose escalation study in patients with small cell lung cancer or large cell neuroendocrine carcinoma with cytologically confirmed, limited or extensive SCLC or LCNEC that have relapsed or refractory limited or extensive disease following no more than 2 prior chemotherapy regimens. (clinicaltrials.gov)
  • In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in adenocarcinoma (Ad), but these mutations have rarely been reported in small cell lung carcinoma (SCLC). (nih.gov)
  • In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide useful information for better understanding the biology, natural history and clinical management of SCLC. (nih.gov)
  • Solitary small bowel metastasis secondary to lung cancer is very uncommon. (hindawi.com)
  • The JTO is a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. (scienceblog.com)
  • The JTO is the official monthly journal of the International Association for the Study of Lung Cancer (IASLC.org) and emphasizes a multidisciplinary approach, including original research (clinical trials and translational or basic research), reviews and opinion pieces. (scienceblog.com)
  • Lung cancer is the most common cause of the malignant pleural effusions(MPE).For patients with lung cancer and MPE, the median survival is only 3-4 months.The aim of this study was evaluate the lung cancer patients with MPE clinical and laboratory findings on admission,analysis of 2 years survival and prognostic factors. (ersjournals.com)
  • What do I need to know about caring for someone with non-small cell cancer? (sharecare.com)
  • Small cell lung cancer (SCLC) is an aggressive lung tumour strongly associated with cigarette smoking, with patients often presenting with metastatic disease at the time of diagnosis. (ersjournals.com)
  • Small cell lung cancer (SCLC) is an aggressive malignant disease, with the majority of patients presenting with distant metastasis at diagnosis. (ersjournals.com)
  • The International Association for the Study of Lung Cancer defines limited-stage SCLC (LS-SCLC) as: "disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular nodes and should also include patients with ipsilateral pleural effusion independent of whether cytology is positive or negative" 2 . (ersjournals.com)
  • Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? (nih.gov)
  • To compare the presenting and prognostic characteristics of patients with large cell neuroendocrine lung cancer (LCNELC) with those of patients with small cell lung cancer (SCLC) or other large cell carcinomas (OLCs) and to compare overall survival (OS) and lung cancer-specific survival (LCSS) rates for patients undergoing definitive resection without radiotherapy (S-NoRT). (nih.gov)
  • Small cell lung cancer, another neuroendocrine tumor, is associated with paraneoplastic syndromes (PNS) in up to 20% of cases, notably the syndrome of inappropriate antidiuretic hormone (SIADH) and Lambert-Eaton myasthenic syndrome. (aad.org)
  • Aside from non-melanoma skin cancer, the most common malignancies in the US are breast cancer followed by lung cancer. (aad.org)
  • anti-epiligrin cicatricial pemphigoid, amongst others may be paraneoplastic disorders that may be secondary to lung cancer. (aad.org)
  • 3. Owen CO. Cutaneous manifestations of lung cancer. (aad.org)
  • It is more commonly associated with non-small-cell lung cancer, but the temporal association with Bowen's disease in the absence of other chemical or occupational exposure strongly points to a causal role for arsenic in this case of small-cell lung cancer. (thefreelibrary.com)
  • A diagnosis of extensive stage small-cell lung cancer was made. (thefreelibrary.com)
  • Listen as Dr. London Smith (.com) and his producer Cameron discuss Small Cell Lung Cancer with special guest Dr. Benjamin Evans. (stitcher.com)
  • It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. (go.jp)
  • This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). (go.jp)
  • We propose that TFP might be capable of inhibiting one or more elements of the DNA DSB repair machinery, thereby increasing the cytotoxicity of bleomycin in lung cancer cells. (aacrjournals.org)
  • This case indicates that metastasis induced acute pancreatitis can be a manifestation of lung cancer, especially in small cell carcinoma. (eurekamag.com)
  • The frequencies of micronuclei were measured in lymphocytes of 6 patients with small cell lung cancer treated with a combination of cisplatin and etoposide and 7 patients with ovarian carcinoma treated with a combination of taxol and cisplatin. (ovid.com)
  • 3 patients with lung cancer received radiotherapy in addition to chemotherapy. (ovid.com)
  • Expression of the protein could have implications for progression of the disease because it regulates cancer cell growth, apoptosis, and angiogenesis. (aacrjournals.org)
  • Sex-dependent effects of PTHrP in lung cancer would open new avenues of research into the role of sex in cancer progression. (aacrjournals.org)
  • It is less widely appreciated that PTHrP also exerts effects direct effects on cancer cells that could be important in the pathology of malignancy. (aacrjournals.org)
  • Direct actions of PTHrP on cancer cells are frequently related to cell growth or life cycle. (aacrjournals.org)
  • For example, the protein alters the rate of proliferation in many cancer cell types ( 1 - 4 ) and can have regulatory effects on the propensity to undergo apoptosis ( 5 - 7 ). (aacrjournals.org)
  • PTHrP also modulates integrin ( 8 - 11 ) and metalloproteinase expression ( 12 ) in various cancer cells and inhibits angiogenesis ( 13 ). (aacrjournals.org)
  • A large body of work has evaluated the role of PTHrP in lung cancer-induced hypercalcemia ( 21 ), but few investigations have probed its role in lung cancer progression or survival. (aacrjournals.org)
  • An animal study from our laboratory suggested that PTHrP expression could hinder lung cancer growth ( 1 ). (aacrjournals.org)
  • Survival of patients with stage II non-small lung cancer by the 1986 classification depends on the type of lymph node involvement (by direct extension or by metastases in lobar or hilar lymph nodes). (ovid.com)
  • Lung cancer is the leading cause of cancer-related death throughout the world ( 1 ). (spandidos-publications.com)
  • Since the lack of symptoms and little help from traditional X-rays on early stage lung cancer, most patients are diagnosed with advanced stage disease and thus have poor prognosis. (spandidos-publications.com)
  • Some studies showed that human testicular orphan nuclear receptor-4 (TR4) repressed the ERβ-mediated transactivation of its downstream signal pathways in lung cancer cells and indicated that TR4 might be a potential tumor suppressor gene ( 17 ). (spandidos-publications.com)
  • Lung Cancer, 74(1):118-123. (uzh.ch)
  • IRAK-1 is a novel inflammation-related marker and a potential target for lung cancer chemopreventive strategies. (pubmedcentralcanada.ca)
  • Lung cancer is the leading cause of cancer-related deaths in the United States ( 1 ). (pubmedcentralcanada.ca)
  • The identification of novel molecular mechanisms involved in the pathogenesis and progression of premalignant lesions may provide with new strategies for risk assessment and early detection, chemoprevention, and treatment of lung cancer. (pubmedcentralcanada.ca)
  • In addition, inflammation and related pathways have been implicated in the pathogenesis of lung cancer, particularly in the tobacco related damage of the respiratory epithelium ( 3 , 7 , 8 ). (pubmedcentralcanada.ca)
  • Background: The ultimate goal of the study was to find a role of curcumin in targeting lung cancer stem cells by reducing their self-renewal efficiency causing DNA damage. (eurekaselect.com)
  • Materials and Methods: Circulating lung cancer stem cells were isolated by sphere formation assay and further analysed by flow-cytometry and qRT-PCR for the presence of stem cell and stem cell transcription markers. (eurekaselect.com)
  • Results and Conclusion: Our results demonstrated that curcumin significantly affect the self-renewal ability of circulating lung cancer stem cells. (eurekaselect.com)
  • Thus, we can conclude that curcumin can be used to target lung cancer stem cells which is responsible for the disease progression and metastasis by causing DNA damage or inhibiting their DNA repair mechanisms. (eurekaselect.com)
  • Sheefa Mirza, Aakanksha Vasaiya, Hemangini Vora, Nayan Jain and Rakesh Rawal*, "Curcumin Targets Circulating Cancer Stem Cells by Inhibiting Self-Renewal Efficacy in Non-Small Cell Lung Carcinoma", Anti-Cancer Agents in Medicinal Chemistry (2017) 17: 859. (eurekaselect.com)
  • In Vietnam, lung cancer has one of the highest death rates, with non-small-cell lung carcinoma accounting for 85% of patients being treated. (fvhospital.com)
  • These studies thus reveal a central role for ID1 and its downstream targets in facilitating lung cancer progression. (springer.com)
  • Sattler and Salgia, 2007 ) so that a detailed understanding of processes underlying c-Met-dependent cancer cell migration is important for providing opportunities for the development of new treatments for these diseases. (biologists.org)
  • A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. (semanticscholar.org)
  • Non-small cell lung carcinoma is a leading cause of cancer mortality worldwide. (diva-portal.org)
  • Wistuba, Ignacio 2018-06-06 00:00:00 Background: The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor types, including lung cancer. (deepdyve.com)
  • Conclusions: NCT-NSCLCs exhibited higher levels of PD-L1 expression and T-cell subset regulationthannon-NCT-NSCLCs, suggesting that NCT activates specific immune response mechanisms in lung cancer. (deepdyve.com)
  • Although neoadjuvant chemotherapy (NCT) liferation, and inflammatory and immune cell activation for cancer has historically been considered immunosup- [1]. (deepdyve.com)
  • GAGE and NY-ESO-1 cancer/testis antigens were not expressed in normal lung tissue, while SP17 was expressed in ciliated lung epithelia. (biomedcentral.com)
  • In lung cancer, K- ras mutations occur predominantly in codon 12 ( 3 )( 4 )( 5 )( 6 )( 7 ). (aaccjnls.org)
  • The timing of K- ras activation in the process of lung cancer development is still unclear. (aaccjnls.org)
  • Several methods have been utilized for the detection of K- ras point mutations in lung cancer. (aaccjnls.org)
  • The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. (ersjournals.com)
  • I read that lung cancer is one of the most common cancers, but what can you do to reduce the risk? (images.md)
  • Adenocarcinoma is the most common type of non-small-cell lung cancer accounting for around 40% of all cases. (images.md)
  • It is commonly found in current or former smokers but paradoxically, it is also the most common type of lung cancer found in people who have never smoked. (images.md)
  • Squamous cell lung carcinoma (also called epidermoid carcinoma) is a cancer that forms in the squamous cells, which are round, flat cells that replace injured or damaged cells in the lining of the lung's bronchi. (images.md)
  • These types of cancer account for around 9 % of all lung carcinomas and tend to be very fast growing. (images.md)
  • Other less common types of non-small cell lung cancer are: pleomorphic, carcinoid tumor, salivary gland carcinoma, and all carcinomas that are histologically unidentifiable known as unclassified lung carcinomas. (images.md)
  • 4. American Cancer Society: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. (images.md)
  • Necrosis is associated with pathologic conditions while apoptosis is a physiological process of programmed cell death, which is associated with normal tissue growth and is frequently impaired in various forms of cancer. (springeropen.com)
  • Tumor necrosis and apoptotic index (AI) have been previously evaluated as prognostic biomarkers in lung cancer, but their exact clinical value remains unclear. (springeropen.com)
  • The prognosis of lung cancer remains poor. (springeropen.com)
  • This is the allocated stage for small-cell lung cancer if the tumours have spread beyond the hemi-thorax, the mediastinum or the supraclavicular lymph nodes of the affected side. (images.md)
  • Of the total number of cases of small-cell lung cancer it is estimated that around two out of three patients already have extensive disease at the time of diagnosis. (images.md)
  • This is due in part to the fact that small-cell lung cancer is an aggressive disease and the tumour or tumours grow and metastasise rapidly, so often by the time that symptoms have manifested the cancer has already spread. (images.md)
  • The most common sites of metastatic spread in lung cancer include the other lung, the adrenal gland or glands, bone, brain and liver. (images.md)
  • Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. (images.md)
  • In 2015, the World Health Organization (WHO) and the International Association for the Study of Lung Cancer (IASLC) updated their guidelines for the subclassification of lung cancers. (nih.gov)
  • Large cell carcinoma of the lung with a rhabdoid phenotype is a rare type of lung cancer, and does not commonly metastasize to the small intestine. (ersjournals.com)
  • Herein we describe a 63-yr-old Japanese male with ileus resulting from small intestinal metastasis from lung cancer. (ersjournals.com)
  • Pulmonary carcinoma is the most frequently diagnosed major cancer, although only a few cases of large cell carcinoma of the lung with rhabdoid phenotype (LCCRP) have been reported [ 1 ]. (ersjournals.com)
  • Metastases to the brain, bone, adrenal glands and liver are more common in patients with lung cancer, whereas small intestinal metastasis is rare [ 2 ]. (ersjournals.com)
  • The differential diagnosis between pleural malignant mesothelioma (MM) and lung cancer is often challenging. (nih.gov)
  • All 45 non-small cell lung cancer biopsies stained positive for nuclear BAP1, whereas 22/35 (63%) MM biopsies lacked nuclear BAP1 staining, consistent with previous data. (nih.gov)
  • To determine cytotoxic effects of single and blended mushroom extracts, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and neutral red assays were conducted using human small cell lung cancer, lung adenocarcinoma, colon cancer, and brain astrocytoma cancer cells. (begellhouse.com)
  • During recent years, the crosstalk between the cancer cells and the tumor stroma, highly responsible for the progression of tumors and their metastasis, has been increasingly unveiled. (upv.es)
  • This review reports novel data on the essential crosstalk between cancer cells and cells of the tumor stroma, with an emphasis on the role played by CAFs. (upv.es)
  • Furthermore, it presents recent literature on relevant tumor stroma- and CAF-related research in non-small cell lung cancer. (upv.es)
  • Lungs - Cancer - Molecular aspects. (hku.hk)
  • Small cell lung cancer (SCLC) or Small Cell Carcinoma (Lung), formerly known as oat cell carcinoma, accounts for 10-15% of all lung cancers. (withoutaribbon.org)
  • However, there is a strong link between the presence or diagnosis of small cell lung cancer and chronic tobacco smoking. (withoutaribbon.org)
  • Other risk factors for developing small cell lung cancer are the working history in uranium mines and long-term exposure to radon gas. (withoutaribbon.org)
  • Worldwide, lung cancer is the most common malignant neoplasm in men and the fifth most common cancer in women. (withoutaribbon.org)
  • In Europe, lung cancer is the 2nd common cancer after prostate cancer. (withoutaribbon.org)
  • Small Cell Carcinoma (Lung) is a rare cancer, meaning it is not as well known as other forms of cancer. (withoutaribbon.org)
  • If you suffer from rare cancer such as Small Cell Carcinoma (Lung), we can help and support you through your journey thanks to the generous donations we receive. (withoutaribbon.org)
  • EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. (rush.edu)
  • A Little Bit of Cancer is Still Cancer: Is it Time for Lymph Node Micrometastases in Non-small Cell Lung Cancer to Get Their Due? (rush.edu)
  • The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. (rush.edu)
  • Here's Boston's Dana-Farber Cancer Center's quick-and-dirty cartoon video about how the anti-PD-1 drug hooks up with the PD-L1 expression on the cancer cell (antigen). (biomednews.org)
  • Months after she'd received the treatment for early-stage adenocarcinoma, a type of non-small cell lung cancer, the woman came back suffering. (biomednews.org)
  • Methods: An analysis of our tumor registry was performed to identify all patients undergoing surgical resection of lung cancer between July 1, 1988, and December 31, 2002, for large cell tumors. (elsevier.com)
  • Accurate differentiation of large cell neuroendocrine carcinoma from large cell carcinoma is important because it identifies those patients at highest risk for the development of recurrent lung cancer. (elsevier.com)
  • Presentation] IASLC 2019 World Conference on Lung Cancer. (pharmaceutical-journal.com)
  • Lung cancer is a malignant neoplasm in the respiratory system (lungs and bronchi). (iheartlung.com)
  • Lung cancer is caused by a change in the genetic material due to chronic damage. (iheartlung.com)
  • Because symptoms are unrecognized or misinterpreted, lung cancer is often discovered by accident during examinations. (iheartlung.com)
  • The treatment of a lung tumor depends on the type of cancer. (iheartlung.com)
  • Thus lung cancer is second only to prostate cancer in males and third in women after breast and colon cancer. (iheartlung.com)
  • The main risk factor for the development of lung cancer is cigarette smoking: Around 85% of all cases can be attributed to tobacco consumption. (iheartlung.com)
  • From surgery to Targeted Therapy: Depending on the type and stage, lung cancer is treated differently. (iheartlung.com)
  • Anyone smoking a pack of cigarettes every day for over 20 years increases their lung cancer risk 30 to 40 times. (iheartlung.com)
  • How does lung cancer develop? (iheartlung.com)
  • Small cell lung cancer (about 20% of the disease) spreads rapidly through the bloodstream and lymphatics, but is better for chemotherapy. (iheartlung.com)
  • In those cases of lung cancer that are discovered at an early stage, these are generally incidental findings: pulmonary x-raying is actually done for quite different reasons, e.g. in case of release for surgical procedures or severe infections suggesting pneumonia. (iheartlung.com)
  • More than two-thirds of all cases of lung cancer are therefore diagnosed at a local or systemic (i.e., distant metastasis) stage. (iheartlung.com)
  • in addition, in the case of lung cancer in the family or a workplace that is burdened by inhaled carcinogens (carcinogenic substances). (iheartlung.com)
  • If lung cancer is suspected, the patient is referred to a specialized department where a complete examination is made as soon as possible. (iheartlung.com)
  • Matrix metalloproteinases (MMPs) are proteolytic enzymes that regulate various cell behaviors in cancer biology, via their basic function of degradation of proteins. (cdc.gov)
  • Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer]. (cdc.gov)
  • Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China', Asian Pacific Journal of Cancer Prevention , 17(3), pp. 965-971. (waocp.org)
  • Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. (cdc.gov)
  • My mom was diagnosed with the same type of lung cancer and had the same surgery you had, on Feb. 3. (whatnext.com)
  • There is a wide range of different drugs which can be applied in treatment of small-cell lung cancer. (therapyselect.de)
  • Small-cell lung cancer is classified into four stages. (therapyselect.de)
  • Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. (cancer.gov)
  • There are several types of non-small cell lung cancer. (cancer.gov)
  • Smoking is the major risk factor for non-small cell lung cancer. (cancer.gov)
  • Signs of non-small cell lung cancer include a cough that doesn't go away and shortness of breath. (cancer.gov)
  • Tests that examine the lungs are used to diagnose and stage non-small cell lung cancer. (cancer.gov)
  • If lung cancer is suspected, a biopsy is done. (cancer.gov)
  • For most patients with non-small cell lung cancer, current treatments do not cure the cancer. (cancer.gov)
  • The bronchi are sometimes also involved in lung cancer . (cancer.gov)
  • Each type of non-small cell lung cancer has different kinds of cancer cells. (cancer.gov)
  • The cancer cells of each type grow and spread in different ways. (cancer.gov)
  • Cancer that forms in the thin, flat cells lining the inside of the lungs. (cancer.gov)
  • Cancer that may begin in several types of large cells. (cancer.gov)
  • Cancer that begins in the cells that line the alveoli and make substances such as mucus . (cancer.gov)
  • Talk to your doctor if you think you may be at risk for lung cancer. (cancer.gov)
  • This is the most important risk factor for lung cancer. (cancer.gov)
  • The earlier in life a person starts smoking, the more often a person smokes, and the more years a person smokes, the greater the risk of lung cancer. (cancer.gov)
  • Having a family history of lung cancer. (cancer.gov)
  • When smoking is combined with other risk factors, the risk of lung cancer is increased. (cancer.gov)
  • Sometimes lung cancer does not cause any signs or symptoms . (cancer.gov)
  • Signs and symptoms may be caused by lung cancer or by other conditions. (cancer.gov)
  • Lung cancer is one of the most prevalent neoplasms and the leading cause of cancer-related death worldwide, being responsible for nearly one in five cases 1 . (nature.com)
  • It is the second most prevalent type of lung cancer after lung adenocarcinoma and it originates in the bronchi. (wikipedia.org)
  • Squamous-cell lung carcinoma share most of the signs and symptoms with other forms of lung cancer. (wikipedia.org)
  • It most often arises centrally in larger bronchi, and while it often metastasizes to locoregional lymph nodes (particularly the hilar nodes) early in its course, it generally disseminates outside the thorax somewhat later than other major types of lung cancer. (wikipedia.org)
  • citation needed] Large scale studies such as The Cancer Genome Atlas (TCGA) have systematically characterized recurrent somatic alterations likely driving lung squamous-cell carcinoma initiation and development. (wikipedia.org)
  • In these cases, the tumors are classified as combined small cell lung carcinoma (c-SCLC), [7] and are (usually) treated like "pure" SCLC. (wikipedia.org)
  • LCLC is differentiated from small cell lung carcinoma (SCLC) primarily by the larger size of the anaplastic cells, a higher cytoplasmic-to-nuclear size ratio, and a lack of "salt-and-pepper" chromatin. (wikipedia.org)
  • We tested the effects of Ganoderma on drug-sensitive (H69) and multi-drug resistant (VPA) human SCLC cells. (nih.gov)
  • When compared untreated controls or SCLC cells treated with extracts of non-cytotoxic Ganoderma species, cells treated with extracts of cytotoxic Ganoderma species responded with an induction of apoptosis similar to cells treated with the chemotherapeutic drugs etoposide and doxorubicin. (nih.gov)
  • Pre-incubation of drug-resistant SCLC cells with cytotoxic Ganoderma reduced the IC(50) for etoposide (3.4-0.21 microM) and doxorubicin (0.19-0.04 microM). (nih.gov)
  • These results show that extracts of several species of Ganoderma are cytotoxic to both drug-sensitive and drug-resistant SCLC cells, are pro-apoptotic, induce gene expression patterns that are similar to SCLC cells treated with chemotherapeutic drugs, and can reverse resistance to chemotherapeutic drugs. (nih.gov)
  • Small cell carcinoma of the lung (SCLC) together with the large cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), and atypical carcinoid (AC) make a group of morphologically identifiable neuroendocrine tumors. (srce.hr)
  • The differential diagnosis of SCLC includes, first of all, other neuroendocrine tumors, and primary or metastatic non-small cell carcinomas. (srce.hr)
  • In contrast, little progress has been made in the treatment of extensive-stage SCLC (ES-SCLC), apart from the recently documented survival gain by the addition of prophylactic cranial irradiation. (ersjournals.com)
  • Recently, prophylactic cranial irradiation (PCI) has been shown to improve outcome in patients with ES-SCLC 4 , but only small advances have been made otherwise. (ersjournals.com)
  • Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). (go.jp)
  • Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. (aacrjournals.org)
  • Consistent with these findings, murine non-neuroendocrine SCLC tumors are rejected in a syngeneic model, with clonal expansion of immunodominant effector CD8 T cells. (aacrjournals.org)
  • Therapeutically, EZH2 inhibition followed by STING agonism enhances T cell recognition and rejection of SCLC in mice. (aacrjournals.org)
  • No novel chemotherapeutic combinations have demonstrated superior efficacy to etoposide/cisplatin (EP), a standard treatment regimen for extensive-stage small cell lung carcinoma (ES-SCLC) over the past decade. (biomedcentral.com)
  • In 2015, large cell neuroendocrine carcinoma (LCNEC) was removed from the large cell carcinoma group and classified with small cell lung carcinoma (SCLC) constituting two members of the high-grade neuroendocrine tumors (NETs) of the lung. (jcancer.org)
  • These results suggested that high-grade LCNEC and high-grade SCLC were different histological types, and that a detailed classification for high-grade NETs of the lung was needed. (jcancer.org)
  • Small cell lung carcinoma (SCLC) is a tumour of neuroendocrine origin often found in association with autoimmune paraneoplastic neurological disorders. (ox.ac.uk)
  • We established a SCLC cell line from a woman with Lambert-Eaton myasthenic syndrome (LEMS) who developed antibodies to both the P/Q-type voltage-gated calcium channels (VGCC) and the muscle acetycholine receptor (AChR). (ox.ac.uk)
  • The results show that many proteins involved in exocytosis are present in the SCLC cells, and that depolarisation-dependent release of [(3)H]-serotonin is linked to calcium influx through P/Q-type VGCCs. (ox.ac.uk)
  • The distinction between small cell lung carcinoma (SCLC) and small cell carcinomas of other sites is difficult by routine histology. (avmi.net)
  • TTF-1 expression has also been demonstrated in adenocarcinomas of the thyroid and lung, and SCLC. (avmi.net)
  • However, the value of TTF-1 immunostaining in discriminating between SCLC and nonpulmonary small cell carcinomas has not been investigated. (avmi.net)
  • Sixteen (89%) of the 18 Merkel cell carcinomas and one SCLC were CK20-positive. (avmi.net)
  • These results indicate that although TTF-1 is not a specific marker for SCLC, it may assist in distinguishing SCLC from some nonpulmonary small cell carcinomas, particularly Merkel cell carcinoma, especially when it is used in conjunction with CK20. (avmi.net)
  • Surgery is the main option, all patients with stages I SCLC lung should undergo surgical resection of the tumour (complete removal of the tumour along with the removal of some surrounding healthy tissues). (withoutaribbon.org)
  • Pneumonectomy (surgical removal of the entire lung), lobectomy (removal of a lobe of a lung) should also be considered in the earlier stages of SCLC when the tumour has spread to most of the lung or lobe of the lung. (withoutaribbon.org)
  • The c-raf-1 oncogene is located at chromosome 3p25, near a region known to be specifically deleted in patients with renal cell carcinoma and small cell lung carcinoma (SCLC). (elsevier.com)
  • From cytogenetic analyses of SCLC cell lines, we have estimated that one c-raf-1 allele was deleted in approximately 80% of the cases. (elsevier.com)
  • Analysis of 73 unpaired lung carcinoma DNAs showed that out of 31 non-SCLC samples, 19% were heterozygous for the BglI polymorphism and 25% showed heterozygosity with TaqI. (elsevier.com)
  • Ten human cell lines, six small cell lung carcinoma (SCLC), one large cell carcinoma (LCC), two neuroblastoma and one lymphoblast-like cell line, were screened with a preprodynorphin cRNA-probe. (scripps.edu)
  • Two of the cell lines, neuroblastoma SK-N-MC and SCLC H69, also expressed preproenkephalin-mRNA. (scripps.edu)
  • Pie chart showing incidences of non-small cell lung cancers as compared to small cell carcinoma shown at right, with fractions of smokers versus non-smokers shown for each type. (wikipedia.org)
  • [9] Adenocarcinomas account for approximately 40% of lung cancers. (wikipedia.org)
  • Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among Japanese. (greenmedinfo.com)
  • The classification of lung cancers are divided into two main categories:- non-small-cell lung carcinoma (NSLC) and small-cell lung carcinoma (SCL) (3) this distinction is useful for therapeutic purposes as management and treatment tends to be similar for non-small-cell lung cancers and quite different for small-cell cancers. (images.md)
  • (4) The three main types of non-small-cell lung cancers, are classified according to the types of cells involved, and are adenocarcinoma (see Image 1), squamous cell carcinoma (see Image 2) and large-cell carcinoma (see image 3). (images.md)
  • Squamous-cell carcinoma is primarily caused by smoking (5) and accounts for around 30% of all lung cancers. (images.md)
  • According to studies around 90 - 95% of small-cell lung cancers are centrally located and usually arise in a main bronchus or a lobar bronchi (a subdivision of the bronchus) and appear as hilar or perihilar growths. (images.md)
  • The remaining 5 - 10% of small-cell lung cancers present in a peripheral position of the lung. (images.md)
  • (3) Small-cell lung cancers tend to be aggressive, so even though the cells are small the tumours grow rapidly and are more widely metastatic (have a greater tendency to spread to other parts of the body) than non-small cell lung cancers. (images.md)
  • Used alone and sometimes in combination with other drugs or modalities, the drugs are forcing a certain percentage of melanomas and smoking-induced lung cancers to yield. (biomednews.org)
  • Considerable debate has emerged as to whether these tumors should be classified and treated as non-small cell lung cancers or small cell lung cancers. (elsevier.com)
  • Results: Of the 2099 patients who underwent resection, 82 (3.9%) had large cell lung cancers. (elsevier.com)
  • Smoking causes 85% of lung cancers. (iheartlung.com)
  • The non-small cell type accounts for around three quarters of cancers of the lung. (iheartlung.com)
  • Owing to the absence of clinical symptoms and effective screening programs, most lung cancers are diagnosed at an advanced stage with metastasis. (nature.com)
  • Recurrent loss-of-function mutations have been observed also in NOTCH1 (8%), suggesting a tumor suppressive role in lung SCC for this gene, that has also been implicated as an oncogene in haematological cancers. (wikipedia.org)
  • Although the criteria for the morphologic separation from other tumors of the lung are defined, in everyday practice it can be a problem, both in cytology and with histological samples. (srce.hr)
  • Other leukocytes such as macrophages (CD14), B lymphocytes (CD20), and natural killer (NK) cells (CD56) were also found to infiltrate the tumors, but in significantly lower numbers. (nih.gov)
  • Two additional RB positive primary tumors have major foci in which all tumor cells showed no RB protein staining. (aacrjournals.org)
  • Keywords: Tumor compartments, Epithelial compartment, Stromal compartment, Adenocarcinoma, Squamous cell carcinoma, Survival, T cells Background suggesting that strategies to control and modify the im- Tumors grow by using a complex composite system that mune cell population are important approaches to can- includes epithelial and stromal cell activation, vessel pro- cer therapy. (deepdyve.com)
  • Wang J, Ye L, Cai H, Jin M. Comparative study of large cell neuroendocrine carcinoma and small cell lung carcinoma in high-grade neuroendocrine tumors of the lung: a large population-based study. (jcancer.org)
  • Among the nonpulmonary small cell carcinomas, two tumors of the gastrointestinal tract, one of the bladder, and one of the uterine cervix exhibited TTF-1 positivity. (avmi.net)
  • Immunohistochemical analysis of tumor sections showed moderate-to-high grade signals for EGFR and adenovirus, and a reduction in viable cells in Ad/SA-treated tumors. (elsevier.com)
  • Objective: Large cell neuroendocrine carcinomas of the lung display morphologic and immunohistochemical characteristics common to neuroendocrine tumors and the morphologic features of large cell carcinomas. (elsevier.com)
  • Similarly, the squamous cell differentiation pathway, whose components include SOX2, TP63 and NOTCH1, is altered in 44% of the tumors. (wikipedia.org)
  • DLC-1 tumor supressor gene induces apoptosis in human non-small cell lung carcinoma cells following a unique process of cell morphological changes and protein nuclear translocation. (cdc.gov)
  • Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2 '-deoxycytidine. (cdc.gov)
  • In the present study, we investigated the effect of trifluoperazine on ( a ) survival of bleomycin-treated human non-small cell lung carcinoma U1810 cells, ( b ) induction and repair of bleomycin-induced DNA strand breaks, and ( c ) nonhomologous end-joining (NHEJ), the major DNA double-strand break (DSB) repair pathway in mammalian cells. (aacrjournals.org)
  • In the present study, we analyzed the effects of TFP on the induction and repair of bleomycin-induced DNA strand breaks in U1810 human non-small cell lung carcinoma cells. (aacrjournals.org)
  • Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed epithelial cells in the lung. (wikipedia.org)
  • Research of Non-small Cell Lung Carcinoma has been linked to Malignant Neoplasm Of Lung, Malignant Neoplasms, Lung Neoplasms, Neoplasms, Carcinoma. (novusbio.com)
  • Qualitative and quantitative testing of circulating cell free DNA (CCFDNA) can be applied for the management of malignant and benign neoplasms. (mdpi.com)
  • Squamous cell carcinomas (SCC) are more frequent among smoking men while females develop adenocarcinomas (ADCA). (diva-portal.org)
  • MATERIAL AND METHODS: Material from 29 cases of lung carcinoma (small cell, squamous cell, and adenocarcinomas) was examined immunohistochemically for Ki-67 and p53 expression in virtually constructed cylinders of different diameters. (diva-portal.org)
  • When Point-EXACCT was used, K- ras codon 12 mutations were detected in 8 of 52 patients with squamous cell carcinomas, 10 of 29 patients with adenocarcinomas, and 3 of 8 patients with large cell carcinomas. (aaccjnls.org)
  • K- ras point mutations are found in approximately 15-56% of the adenocarcinomas and to a lesser extent in other types of non-small cell lung carcinomas (NSCLCs) ( 3 )( 5 )( 7 )( 8 )( 9 )( 10 )( 11 )( 12 )( 13 )( 14 ). (aaccjnls.org)
  • Selected agents ( e.g. pemetrexed and nintedanib) show superior efficacy in adenocarcinomas and large cell carcinomas when compared to squamous cell carcinomas (SqCC) [ 2 - 5 ]. (ersjournals.com)
  • (2) Adenocarcinomas usually occur in the peripheral (or outer) portion of the lungs. (images.md)
  • Tumour is on the left, obstructing the bronchus (lung). (wikipedia.org)
  • In line with the isoform-specific requirement of ERK2 for HGF-mediated migration in lung tumour cell models, ERK2 but not ERK1 is shown to be responsible for paxillin serine 126 phosphorylation and its increased turnover at focal adhesions. (biologists.org)
  • The tumour contains dense core granules similar to the argentaffin cell granules of the gastrointestinal tract and actively secretes hormones and hormone like products. (gpnotebook.com)
  • oat cell tumour - characterised by uniform small - to - medium sized, closely packed cells arranged in strands, clusters, or singly, with dark-staining nuclei and a high nuclear:cytoplasmic ratio. (gpnotebook.com)
  • Liquid biopsies ( i.e. analysis of cell-free tumour DNA from blood plasma) have become another important option in such a situation, but are not within the scope of this review. (ersjournals.com)
  • If these lesions grow to a large size hollow cavities appear that are associated with cell death and commonly found at the centre of the tumour, as demonstrated in the above case. (images.md)
  • Large-cell carcinoma is a name that is given to any tumour that cannot be definitively histologically classified as a small-cell, squamous-cell or adenocarcinoma. (images.md)
  • We used a range of techniques to establish which neuronal antigens were expressed in her tumour cell line. (ox.ac.uk)
  • Frontal Chest X-Ray demonstrating a small visible tumour confined to the left upper lobe of the lung with no mediastinum (the membranous partition between the lungs) involvement and no signs of supraclavicular ipsilateral lymph nodes involved. (images.md)
  • There is a lower lung nodule noted on the right lung (purple circle) that is suggestive of a secondary tumour indicating metastatic spread to the opposite lung. (images.md)
  • Based on these clinical findings, we diagnosed the patient as having primary lung tumour with metastasis to the small bowel. (ersjournals.com)
  • Large tumour cells were mainly located in the submucosa and invaded the vessel (arrow) (haematoxylin and eosin stain. (ersjournals.com)
  • Pathological findings of the specimen showed several large tumour cells similar to those in the intestinal lesion shown in (a). (ersjournals.com)
  • c) Enlarged view of boxed section in (b) showing several large tumour cells (arrow). (ersjournals.com)
  • However, the lung tumour quickly enlarged and pleural effusion developed within 3 weeks. (ersjournals.com)
  • This is most often the case when a pathologist examines a small amount of malignant cells or tissue in a cytology or biopsy specimen. (wikipedia.org)
  • Bronchoscopy revealed a right middle-lobe tumor, and the biopsy was positive for small-cell lung carcinoma. (thefreelibrary.com)
  • In 1993, a skin biopsy of a lesion on his right elbow was positive for squamous cell carcinoma in situ. (thefreelibrary.com)
  • Small samples (biopsy and cytology) require "tissue" management, which is best achieved by the interaction of all physicians involved. (ersjournals.com)
  • We performed percutaneous needle biopsy of the lung lesion for diagnosis. (ersjournals.com)
  • On pathological examination of the resected small bowel tissue ( fig. 2a ) and the lung biopsy specimen ( fig. 2b and c), the microscopic appearances of these specimens were identical. (ersjournals.com)
  • b) Lung specimen obtained by percutaneous needle biopsy. (ersjournals.com)
  • Histopathology requires at least a lung biopsy. (wikipedia.org)
  • Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. (nih.gov)
  • Promoter activity of S100A2 was greatly restricted to tumor cells, and the S100A2 promoter bound with typical nuclear targets of epidermal growth factor receptor (EGFR) signaling. (elsevier.com)
  • Its tumor cells are characterized by a squamous appearance, similar to the one observed in epidermal cells. (wikipedia.org)
  • To the best of our knowledge, this is the first case report describing a prolonged survival in a patient with a symptomatic solitary small bowel metastasis treated with palliative surgery, chemo- and radiotherapy instead of complete surgical resection. (hindawi.com)
  • Studies on cellular responses to ionizing radiation have shown that DSBs are extremely toxic and production of ionizing radiation-induced DSBs correlates with impeded cell survival ( 9 ). (aacrjournals.org)
  • It has been hypothesized that chronic inflammation is a major consequence of certain environmental factors eventually leading to increased proliferation, survival, and migration of epithelial cells, as well as angiogenesis in the adjacent stroma, thereby promoting epithelial tumor development ( 4 - 6 ). (pubmedcentralcanada.ca)
  • Overall survival by histologic subtype at 5 years was 30.2% for patients with large cell neuroendocrine carcinomas (n = 45), 30.3% for patients with mixed large cell neuroendocrine carcinomas (n = 11), and 71.3% for patients with large cell carcinomas (n = 21). (elsevier.com)
  • Survival was significantly worse for patients with large cell neuroendocrine carcinomas than for patients with large cell carcinomas (P = .013). (elsevier.com)
  • 001). Conclusion: Patients with large cell neuroendocrine carcinomas have a significantly worse survival after resection than patients with large cell carcinomas, even in stage I disease. (elsevier.com)
  • Taking nivolumab for advanced non-small cell lung carcinoma is associated with a better five-year survival rate than taking docetaxel. (pharmaceutical-journal.com)
  • [10] [11] However, recent studies suggest that the "ratio of centrally-to-peripherally occurring" lesions may be converging toward unity for both adenocarcinoma and squamous cell carcinoma. (wikipedia.org)
  • However, acute pancreatitis caused by metastatic carcinoma of the pancreas is an uncommon condition with a poor prognosis. (eurekamag.com)
  • Association of HAb18G with clinicopathologic features and prognosis in non-small cell carcinoma of lung]. (semanticscholar.org)
  • bcl-2 and prognosis in non-small-cell lung carcinoma. (ox.ac.uk)
  • An abdominal CT showed a well-defined lesion in the superior right hepatic lobe consistent with a hepatic cyst and a mildly enlarged and heterogeneous left hepatic lobe concerning for possible hepatocellular carcinoma. (hindawi.com)
  • Current clinical practice guidelines recognize EGFR, BRAF, ALK, and ROS1 as essential molecular biomarkers, and a host of other genetic alterations as emerging biomarkers for non-small cell lung carcinoma patients. (cdc.gov)
  • Cytologic specimens for diagnosis or for cell type classification must have been obtained from bronchial brushings or washings or from needle aspiration of a defined lesion. (pfizer.com)
  • Human normal bronchial and alveolar epithelial cells were also reported to express ERβ, which was considered to contribute to the maintenance of normal lung tissue ( 7 ). (spandidos-publications.com)
  • Frontal Chest X-Ray indicating bronchial Carcinoma. (images.md)
  • Findings: Adenocarcinoma: Bronchial carcinoma with lymphadenopathy. (images.md)
  • Small-cell carcinomas are thought to originate from neuroendocrine cells that can be found in the bronchial mucosa. (images.md)
  • In Austria, around 2,500 men and almost 1,200 women suffer from bronchial carcinoma each year. (iheartlung.com)
  • In 76% of cases (38/50) cytological diagnosis of small cell lung carcinoma was also confirmed histologically. (srce.hr)
  • In 8% of cases (4/50) adenocarcinoma was histologically confirmed, in 10% (5/50) of the cases the squamous carcinoma was confirmed, and there was one case of urothelial carcinoma, one case of sarcoma and one undifferentiated carcinoma. (srce.hr)
  • These lesions were characterised histologically by the presence of typical rhabdoid cells, which are large cells with abundant cytoplasm and eccentric nuclei with central macronucleoli. (ersjournals.com)
  • The antibodies bind to normal human cells to a much lesser degree than to tumor cells. (freepatentsonline.com)
  • In general in tumor tissue, a variable number of nonmalignant cells, such as stromal and inflammatory cells, are mixed with tumor cells. (aaccjnls.org)
  • Because K- ras mutations can be present in only a subpopulation of the tumor cells ( 12 ), a highly sensitive assay is required for the detection of these mutations. (aaccjnls.org)
  • These results reveal that these extracts exhibit different cytotoxic effects on tumor cells originating from different tissues. (begellhouse.com)
  • The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. (freepatentsonline.com)
  • Resulting necrosis is characterized by the presence of dead cells in the form of anucleate "ghost cells', but with preservation of the tissue architecture (Kumar et al. (springeropen.com)
  • EN] Maintenance of both normal epithelial tissues and their malignant counterparts is supported by the host tissue stroma. (upv.es)
  • A squamous-cell carcinoma is often preceded for years by squamous-cell metaplasia or dysplasia in the respiratory epithelium of the bronchi, which later transforms to carcinoma in situ. (wikipedia.org)
  • Early squamous-cell carcinoma of the lung (generally as squamous-cell carcinoma in situ) is asymptomatic and may only appear as an incidental imaging finding on CT scan or magnetic resonance imaging as a lung nodule. (wikipedia.org)
  • New studies revealed that DLC-1 transfection can initially induce multiple branched cytoplasmic extensions, which are followed by membrane blebbing along the cytoplasmic extensions and progressive cell shrinkage, and ended with cytoplasmic and nuclear decomposition, the morphological evidence of cell apoptosis. (cdc.gov)
  • We have previously described a group of non-small cell lung carcinomas without morphological evidence of neo-angiogenesis. (ox.ac.uk)
  • Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. (ox.ac.uk)
  • [1] [2] As a class, NSCLCs are relatively insensitive to chemotherapy , compared to small cell carcinoma. (wikipedia.org)
  • Thirteen months earlier, he developed small cell carcinoma of the lung and received 6 cycles of chemotherapy. (eurekamag.com)
  • Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung. (deepdyve.com)
  • In normal situations, T lymphocytes recognize ma- pressive, it is now accepted that certain chemotherapy lignant cells as abnormal and activate cytotoxic T lym- agents, such as paclitaxel, cisplatin, gemcitabine, and phocytes through helper T cells at the site, which carboplatin, can regulate and modulate antitumor im- infiltrate and kill the malignant cells. (deepdyve.com)
  • Chemotherapy has a potential to trigger nant cells have developed sophisticated mechanisms and immune activation by inducing immunogenic cell death pathways through which they regulate negative and posi- and subsequent tumor-associated neoantigen release, tive signals, blocking cytotoxic T cell activation and which in turn activates antigen-presenting cells (APCs) regulatory T cells and thus promoting tumor growth and such as tumor-associated macrophages (TAMs) and eventual tumor metastasis [2]. (deepdyve.com)
  • These pathways complement our catalog of research reagents for the study of Non-small Cell Lung Carcinoma including antibodies and ELISA kits against EGFR, TP53, VEGFA, MID1, CDKN2A. (novusbio.com)
  • No somatic mutations were detected in the mutation cluster regions of the KRAS, EGFR, BRAF and PIK3CA genes and the entire coding region of p53 in the carcinoma, and the expression of ALK fusion was negative. (spandidos-publications.com)
  • On August 31st2019, Ho Chi Minh City Oncology Hospital cooperated with AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, to hold a Scientific Seminar About Diagnosing and Treating Non-Small-Cell Lung Carcinoma Having EGFR Mutation for doctors to discuss and share their experiences in treating the condition. (fvhospital.com)
  • Conversely, the two main driver oncogenes of the latter, EGFR and KRAS, are rarely mutated in lung SCC. (wikipedia.org)
  • The objective of this study was to report the outcome of surgical resection in patients with large cell neuroendocrine carcinomas. (elsevier.com)
  • Cases were then segregated into large cell neuroendocrine carcinomas, mixed large cell neuroendocrine carcinomas (in which at least one portion of the tumor was a large cell neuroendocrine carcinoma), or large cell carcinomas on the basis of morphology and differentiation. (elsevier.com)
  • Cox proportional hazards model analysis incorporating the variables of age, sex, histology, and stage estimated the effect of large cell neuroendocrine carcinomas and mixed large cell neuroendocrine carcinomas on recurrence and death. (elsevier.com)
  • This is also called epidermoid carcinoma. (cancer.gov)
  • This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have progressed through first line systemic therapy containing an immune checkpoint inhibitor (ICI). (clinicaltrials.gov)
  • Ursolic Acid and oleanolic acid reduced the proliferation of A549 cells in nude mice. (greenmedinfo.com)
  • In a small interfering RNA (siRNA)-based high-throughput wound healing screen performed in A549 lung carcinoma cells, we identified ERK2 but not ERK1 as a strong mediator of HGF-induced motility. (biologists.org)
  • It accounts for about 20 - 30% of lung tumours. (gpnotebook.com)
  • Squamous cell tumours usually occur in the central portion of the lung or in one of the main airway branches. (images.md)
  • Large-cell lung carcinoma refers to a diverse group of malignant tumours that originate from the epithelial cells of the lung. (images.md)
  • Approximately 30% of small-cell lung tumours are found at this stage as seen in Image 1. (images.md)
  • In these tumours neoplastic cells fill up the alveoli and the only vessels present appear to belong to the trapped alveolar septa. (ox.ac.uk)
  • In the present study we have characterised the phenotype of the vessels present in these non-angiogenic tumours, in normal lung and in angiogenic non-small cell lung carcinomas. (ox.ac.uk)
  • High level of serum CRP,lower serum albumin,lower pleural protein,MPE with distant metastasis were determined to be the most important prognostic factors for non small cell lung carcinoma patients with MPE. (ersjournals.com)
  • Concomitant therapy with other anti-neoplastic agents or experimental agents except for small volume radiation to a solitary bony metastasis. (knowcancer.com)
  • To our knowledge, there are no previous case reports describing intussusception of the small intestine caused by small intestinal metastasis of LCCRP. (ersjournals.com)
  • Although most host cells in the stroma possess certain tumor-suppressing abilities, the stroma will change during malignancy and eventually promote growth, invasion, and metastasis. (upv.es)
  • A monoclonal antibody (mAb L6) to a small-cell lung carcinoma surface antigen recognizes a common epitope of vasopressin-neurophysin and oxytocin-neurophysin in hypothalamic nuclei. (pnas.org)
  • Transient EZH2 inhibition expands these non-neuroendocrine cells, which display intrinsic innate immune signaling and basally restored antigen presentation. (aacrjournals.org)
  • Expression rate also associated more so with adenocarcinoma histology (39 percent) than in squamous cell carcinoma histology (23 percent). (scienceblog.com)
  • Tumor necrosis and the apoptotic index (i.e. the proportion of apoptotic cells in tumor specimens) are two such features. (springeropen.com)
  • Densities of CD3+ cells in the tumor epithelial compartment were higher in NCT-ADCs and NCT-SCCs than in non-NCT-ADCs and non-NCT-SCCs (P = 0.043). (deepdyve.com)
  • 0.001) cells in the tumor epithelial compartment. (deepdyve.com)
  • Thyroid transcription factor-1 (TTF-1) is a homeodomain-containing transcription factor that is selectively expressed in thyroid and pulmonary epithelial cells. (avmi.net)
  • A case of Bowen's disease and small-cell lung carcinoma: long-term consequences of chronic arsenic exposure in Chinese traditional medicine. (thefreelibrary.com)
  • The patient was diagnosed with Bowen's disease and developed extensive-stage small-cell carcinoma of the lung 10 years and 47 years, respectively, after the onset of arsenic exposure. (thefreelibrary.com)
  • Findings: Small-Cell Lung Carcinoma Limited Stage Disease. (images.md)
  • In clinical practice and research trials small-cell carcinoma is divided into two main classifications which are:- limited and extensive disease. (images.md)
  • Squamous-cell lung carcinoma is one of the tumor types with the highest number of mutations since smoking, the main driver of the disease, is a strong mutagenic factor. (wikipedia.org)
  • Pulmonary large cell neuroendocrine carcinoma: a true high-grade neuroendocrine tumor needing prospective therapeutic data. (nih.gov)
  • DelveInsight's, " Non-Small Cell Lung Carcinoma-Pipeline Insights, 2018", report provides in depth insights on the pipeline drugs and their development activities around the Non-Small Cell Lung Carcinoma. (marketreport.jp)
  • In contrast with stage II, complete resection of pathologic N1 higher-stage non-small cell lung carcinoma is not influenced by type of lymph node involvement. (ovid.com)
  • We have attempted to standardize our lung resection technique using 6 areas of dissection to gain in efficacy and save time. (websurg.com)
  • During emergency surgery, the patient underwent segmental resection of the region of the small bowel showing intussusception along with the flexure of the small bowel. (ersjournals.com)
  • I, too, had a lung resection (lower left lobe) and "chose" no further treatment. (whatnext.com)
  • Small cell carcinomas grow and metastasize rapidly, quickly dividing and spreading to other organs and parts of the body even before they are diagnosed or show symptoms. (withoutaribbon.org)
  • Researched pathways related to Non-small Cell Lung Carcinoma include Angiogenesis, Cell Cycle, Cell Proliferation, Cell Growth, Methylation. (novusbio.com)
  • Sputum cytology alone will not be acceptable for diagnosis or for cell type classification. (pfizer.com)
  • In the remaining 77 patients, histological verification of cytological diagnosis was not made and the patients were treated based on cytological diagnosis of small cell carcinoma. (srce.hr)
  • The recent discovery of fusion oncokinases in a subset of non-small cell lung carcinomas (NSCLCs) is of considerable clinical interest, since NSCLCs that express such fusion oncokinases are reportedly sensitive to kinase inhibitors. (spandidos-publications.com)
  • Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. (aad.org)
  • Additional cell free DNA species, such as cell-free mitochondrial DNA (mtDNA) are also under evaluation for clinical relevance [ 5 ]. (mdpi.com)
  • These findings suggest expression of a pro-pressophysin-like protein in this tumor cell line that is preferentially targeted to the cell membrane. (pnas.org)
  • In addition there is a small left pleural effusion (pleural effusion is an execess of fluid that gathers in the pleural cavity). (images.md)
  • The pleural cavity normally contains a small amount of fluid that helps the lungs move smoothly in the chest when you breathe. (cancer.gov)
  • Can bronchoalveolar carcinoma be prevented? (sharecare.com)
  • Because little is known about the actual cause of bronchoalveolar carcinoma, little is known about how to prevent it. (sharecare.com)
  • How do I manage bronchoalveolar carcinoma on a daily basis? (sharecare.com)
  • If you have been diagnosed with bronchoalveolar carcinoma, it is important to begin treatment immediately to prevent the malignant tumor from metastasizing (spreading). (sharecare.com)
  • Because bronchoalveolar carcinoma cells are known to be spread out throughout the lungs, it is crucial that you find and remove cancerous cells as soon as possible. (sharecare.com)
  • Ask your doctor how to stay healthy while being treated for bronchoalveolar carcinoma. (sharecare.com)
  • Cytopathology may detect atypical cells from cytologic smear test of sputum, bronchoalveolar lavage, or samples from endobronchial brushings. (wikipedia.org)
  • The vessels, identified by the expression of CD31, were scored as mature when expressing the epitope LH39 in the basal membrane and as newly formed when expressing alphaVbeta3 on the endothelial cells and/or lacking LH39 expression. (ox.ac.uk)
  • Immunostaining of endothelial cells has highlighted four distinct patterns of vascularization. (ox.ac.uk)
  • In the nine putative non-angiogenic cases examined, the vascular phenotype of all the vessels was the same as that of alveolar vessels in normal lung: LH39 positive and alphaVbeta3 variable or negative. (ox.ac.uk)
  • Three patterns (which we called basal, papillary, and diffuse) have in common the destruction of normal lung and the production of newly formed vessels and stroma. (ox.ac.uk)
  • Therefore, LCNELC should continue to be classified and treated as a large cell carcinoma. (nih.gov)
  • Identity, similarity, and difference between large cell neuroendocrine carcinoma and small cell carcinoma. (nih.gov)
  • There is a large peripheral mass visible in the left upper lobe next to the oblique fissure, (in the left lung, the oblique fissure separates the superior or upper lobe from the inferior or lower lobe). (images.md)
  • Large-cell carcinomas are so named because the cells appear large and rounded under a microscope with excess cytoplasm cytoplasm (all the material in a living cell except the nuclei) and large nuclei. (images.md)
  • A large mass is visible in the left lung with an area of increased density (showing as an opacity or lightened area) that extends to the upper lung. (images.md)
  • Therefore, the use of relatively insensitive methods for point mutation detection, which can not discriminate cells containing a mutation in a background of cells with wild-type DNA, could lead to underestimation of positive cases. (aaccjnls.org)
  • Computed tomography (CT) scans demonstrated a mass in the right lung ( fig. 1b and c), intussusception of the small intestine ( fig. 1d ) and lymph node enlargement in the abdomen. (ersjournals.com)
  • Miličić V, Prvulović I, Mišić M, Perić M, Samardžić S, Tomić K. Value of Cytology in Small Cell Lung Carcinoma Diagnostic - Single-Center Study. (srce.hr)
  • Merkel cell polyomavirus infection and Merkel cell carcinoma. (aad.org)
  • and similar patterns changes in the expressions of 9 genes involved in the cell cycle/apoptosis, as measured by RT-PCR and capillary electrophoresis. (nih.gov)
  • Cells were stimulated with nicotine and genes that were differentially expressed upon nicotine stimulation and ID1 depletion were analyzed to identify potential downstream targets of ID1. (springer.com)